Topics

α-Synuclein Aggregation Elimination

Proteostasis Neurodegeneration Cellular Degeneration Mitochondrial Dysfunction

α-Synuclein aggregation elimination refers to cellular or therapeutic processes that reduce pathogenic α-synuclein species through protein quality control, degradation, or targeted clearance. α-Synuclein is a major component of Lewy bodies and Lewy neurites, while soluble oligomeric conformations can also exert cellular toxicity, making the abundance and physical state of α-synuclein central questions in Parkinson disease and related synucleinopathies. Research on protein aggregation in neurodegeneration dates to the early twentieth century, but the field has shifted from viewing large fibrillar inclusions as the principal toxic species toward examining oligomers, misfolded intermediates, and the mechanisms controlling their turnover. Neurons rely on molecular chaperones, the ubiquitin-proteasome system (UPS), and the autophagy-lysosomal pathway (ALP) to maintain protein homeostasis; dysfunction of these systems has therefore made α-synuclein clearance an intensively investigated therapeutic direction. This framework connects α-synuclein aggregation directly with proteostasis, neuronal dysfunction, and the search for disease-modifying strategies rather than solely symptomatic treatment. α-Synuclein elimination operates through interconnected proteolytic mechanisms whose relative contributions depend on the biochemical state of the protein[1][2].

The UPS primarily handles soluble intracellular proteins, whereas lysosomal mechanisms, including macroautophagy and chaperone-mediated autophagy (CMA), provide additional routes for α-synuclein disposal; failure of either system can reinforce protein accumulation and disrupt proteostasis. In CMA, cytosolic HSC70 recognizes substrate proteins and delivers them to lysosomal LAMP2A for translocation and degradation. Parkinson-associated perturbations illustrate the importance of this pathway: mutant GBA1-derived glucocerebrosidase can accumulate at the lysosomal surface, inhibit CMA, and cause accumulation of CMA substrates including α-synuclein, while mutant LRRK2 impairs CMA-mediated α-synuclein degradation and promotes age-dependent oligomer accumulation. Conversely, pharmacological CMA activation increased LAMP2A transcription and lysosomal activity and attenuated intracellular and extracellular α-synuclein oligomer accumulation in mutant neuronal cultures. Proteasome homeostasis represents a complementary intervention point because proteasomal dysfunction and protein accumulation can form a reinforcing cycle, motivating approaches that increase proteasomal degradation while preserving global protein homeostasis. Drug discovery is increasingly moving from nonspecific enhancement of proteostasis toward selective elimination of pathogenic α-synuclein[1][3][4][5].

Targeted protein degradation approaches, including PROTAC-related strategies, seek to recruit endogenous degradation machinery to proteins implicated in Parkinson disease, although aggregate degradation presents a particular challenge for proteasome-dependent technologies. AUTOTAC addresses this limitation by coupling α-synuclein aggregate recognition to p62/SQSTM1-dependent macroautophagy: the experimental compound ATC161 promoted selective aggregate degradation, targeted cargo toward autophagic membranes and lysosomes, reduced α-synuclein propagation, and improved pathological and functional measures in cellular and mouse Parkinson models. These results establish aggregate-selective autophagic degradation as a preclinical therapeutic direction, but major translational questions remain. The field still needs to define how different proteolytic systems divide responsibility among monomeric, oligomeric, and fibrillar α-synuclein, how degradation pathways interact during disease progression, and how they can be activated without broadly disturbing essential proteostasis. Future development therefore depends on substrate-selective degraders, precise CMA or lysosomal modulation, mechanistic biomarkers of target clearance, and demonstration that sustained α-synuclein elimination produces clinically meaningful disease modification.[1][3][5][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-100558 Bafilomycin A1
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H+-ATPase (V-ATPase) with IC50 values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis.

Source: Streptomyces griseus strains

Proton Pump   Autophagy   Antibiotic   Bacterial   Apoptosis  
Infection  
947
HY-10256 Adezmapimod
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.
Organoid   p38 MAPK   Autophagy   Mitophagy   HSP  
Lung Cancer   Prostate Cancer   Gastric Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
654
HY-100218A RSL3
RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
p62   Glutathione Peroxidase   Ferroptosis   Reactive Oxygen Species (ROS)  
Ovarian Cancer  
596
HY-13757 Tamoxifen Citrate
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.
Estrogen Receptor/ERR   HSP   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Digestive System Inflammation   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
281
HY-13757A Tamoxifen
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757).
Estrogen Receptor/ERR   HSP   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Digestive System Inflammation   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
281
HY-N0830B Palmitic acid sodium
Palmitic acid sodium is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid sodium can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells. Palmitic acid sodium is used to establish a cell steatosis model .

Source: Widespread

Environmental Pollutants   HSP   Endogenous Metabolite  
Cancer  
128
HY-N0830 Palmitic acid
Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells. Palmitic acid is used to establish a cell steatosis model.

Source: Widespread

Environmental Pollutants   HSP   Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
128
HY-L028 CNS-Penetrant Compound Library
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneficial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 1,199 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

Compound Characteristic Classified Libraries

105
HY-L003 Apoptosis Compound Library
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 3,690 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Signaling Pathway Targeting Libraries

104
HY-L010 MAPK Compound Library
MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers. MCE designs a unique collection of 1,182 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Signaling Pathway Targeting Libraries

102
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 840 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

102
HY-L086 Neurodegenerative Disease-related Compound Library
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour. MCE offers a unique collection of 3,816 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Disease Focused Libraries

99
HY-L134 Anti-Aging Natural Product Library
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases. Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

Natural Product Screening Libraries Disease Focused Libraries

99
HY-L029 Autophagy Compound Library
Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease. MCE provides a unique collection of 2,100 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Signaling Pathway Targeting Libraries

98
HY-L034 Anti-Aging Compound Library
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 7,843 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Disease Focused Libraries

98
HY-L050 Ubiquitination Compound Library
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 507 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Signaling Pathway Targeting Libraries

98
HY-L070 Neuroprotective Compound Library
Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases. MCE offers a unique collection of 1,870 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Compound Characteristic Classified Libraries

98
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 555 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

98
HY-L085 Anti-Parkinson's Disease Compound Library
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD. MCE offers a unique collection of 2,232 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

Disease Focused Libraries

97
HY-L128 E3 Ligase Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2). MCE carefully prepared a unique collection of 184 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

97
HY-L129 Target Protein Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance. MCE carefully prepared a unique collection of 130 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

97
HY-L133 Cuproptosis Compound Library
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis". The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis. Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism. Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis. MCE supplies a unique collection of 457 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.

Signaling Pathway Targeting Libraries

97
HY-L137 Molecular Glue Compound Library
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 126 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Compound Characteristic Classified Libraries

97
HY-L162 Cell Death Library
Cell death plays a crucial role in the development of the body and the maintenance of internal balance to prevent the development of diseases. According to the regulation of the involved processes, cell death can be defined as programmed and non-programmed death. Programmed cell death (PCD) can be divided into lytic cell death and nonlytic cell death, mainly including apoptosis, necrotic apoptosis and Pyroptosis. Non-Programmed cell death (Non-PCD) generally refers to necrosis. In stark contrast to Accidental Cell Death (ACD), Regulatory Cell Death (RCD) relies on specialized molecular mechanisms. Cell death includes internal apoptosis, external apoptosis, necrotic apoptosis, ferroptosis, pyroptosis, lysosome-dependent cell death, etc. MCE designs a unique collection of 3,890 cell death compounds, covering multiple targets, such as Apoptosis, Ferroptosis, Pyroptosis, Necroptosis, etc. It is a useful tool for screening cell death drugs.

Compound Characteristic Classified Libraries

97
HY-L162M Cell Death Inhibitor Library Mini
Cell death is a core biological process that maintains homeostasis in multicellular organisms, playing a dual role in life activities. On one hand, cell death participates in physiological processes such as cell renewal and damage repair through precise regulation; on the other hand, it actively eliminates damaged, infected, or cancerous cells, thereby blocking pathological progression and preserving organism health. Cell death not only ensures the normal development and growth regulation of organisms but is also closely associated with the occurrence and development of various diseases. Numerous studies have shown that specific types of programmed cell death play critical roles in disease progression, providing an important theoretical basis for developing novel therapeutic strategies by regulating cell death pathways. MCE offers 23 types of commonly used cell death inhibitors, such as apoptosis, ferroptosis, pyroptosis, and cuproptosis, suitable for use as positive controls in the study of novel cell death mechanisms.

Signaling Pathway Targeting Libraries

97
HY-L174 Macrophage Related Compound Library
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance. MCE designs a unique collection of 286 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.

Compound Characteristic Classified Libraries

97
HY-L193 PBCRBS Traditional Chinese Medicine Compound Library
Since ancient times, promoting blood circulation for removing blood stasis (PBCRBS) has been one of the most popular research contents in the area of traditional Chinese medicine (TCM) and integrated medicine. Rhizoma, Persicae Semen, Carthami Flos, Curcumae Longae Rhizoma and so on are common TCM with PBCRBS characteristic. Studies have shown that the mechanism of action of PBCRBS TCM is to promote blood circulation (improving cardiovascular and cerebrovascular functions, physical and chemical properties of blood, platelet and coagulation system and other physiological functions) and remove blood stasis (anti-myocardial ischemia, cerebral ischemia, inhibition of platelet aggregation, anti-coagulation, anti-thrombosis, etc.). Not only that, PBCRBS TCM has anti-infection, inhibit inflammation, regulate immune function, inhibit immune response, inhibit abnormal tissue proliferation and other functions. Therefore, PBCRBS TCM has high research value in all- field disease research fields. MCE can supply 1,010 monomer component from more than a hundred sources of PBCRBS TCM, which can be used in TCM studies, drug development and mechanism-based studies.
97
HY-L237 Pattern Recognition Receptors Library
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions. MCE has cataloged 342 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
97
HY-L243 Quinones Library
Quinone compounds are a significant class of natural products featuring a conjugated quinone structure, widely distributed in plants, fungi, and microorganisms. Based on their core structures, they can be primarily categorized into benzoquinones, naphthoquinones, phenanthrenequinones, and anthraquinones, among others. This structural diversity endows quinone compounds with a broad spectrum of pharmacological activities, making them key components in traditional Chinese medicine (such as rhubarb, Lithospermum erythrorhizon, and Salvia miltiorrhiza). Modern research has confirmed that their activities encompass anti-tumor, anti-inflammatory, antibacterial, antiviral, antiplatelet aggregation, and neuroprotective effects, among others, establishing them as an important source for drug development. MCE designs a unique collection of 96 quinones that all come from natural products. MCE Quinones Library is a useful tool for drug discovery that can be used for high throughput screening (HTS) and high content screening (HCS).

Structure Classified Natural Product Libraries

97
HY-L245 Natural Product Diversity Scaffold Library
At the forefront of innovative drug discovery, every medicinal chemist faces the challenge of rapidly identifying high-quality hit compounds from vast repositories of chemical resources. The MCE Natural Product Diversity Scaffold Library is the result of a streamlined optimization process built upon our existing natural product collection. Adhering to the rigorous selection principle of "retaining only one representative compound per BMS scaffold", we have concentrated the diversity of thousands of compounds into a high-value, low-redundancy core set containing 2,248 compounds. All compounds are derived from natural sources, inheriting their inherent advantages of structural complexity and drug-likeness. By eliminating redundancy, the library size is significantly reduced without any compromise to chemical diversity. This approach effectively lowers the cost and time required for primary screening while simplifying downstream data analysis and structure-activity relationship (SAR) studies.

Natural Product Screening Libraries

97
HY-L257 Azide PROTAC Linker Library
Linkers, as key structural units in PROTAC molecules that connect the two functional ends, not only determine the overall molecular conformation and spatial compatibility but also directly influence the stability of the ternary complex, as well as cellular permeability and degradation efficiency. In recent years, with the widespread application of click chemistry in medicinal chemistry, the incorporation of bioorthogonal reactive groups such as azides (-N3) into PROTAC linker design has become an emerging research focus, providing an important tool for modular assembly and rapid structural optimization. The MCE Azide PROTAC Linker Library contains 190 linkers specifically designed for targeted protein degradation molecule design and optimization. These linkers serve as efficient “click handles,” enabling rapid and highly selective covalent coupling with alkyne reaction partners, thereby facilitating modular assembly and structural diversification of PROTAC molecules. In drug development, this design not only improves the efficiency of molecular construction but also significantly accelerates the screening and optimization of lead compounds. Meanwhile, by tuning linker properties such as length, flexibility, and polarity, the ability to form ternary complexes and degradation activity can be optimized.
97
HY-L259 Alkyne PROTAC Linker Library
In PROTAC drug development, linkers are often one of the key variables determining drug-likeness and degradation efficiency. Since PROTAC systems must simultaneously satisfy target protein binding, E3 ligase recruitment, and intracellular spatial conformational matching, their structural design is essentially a multi-parameter optimization problem. Differences in linker rigidity, flexibility, and spatial extension can significantly influence the formation pathway and stability of the ternary complex, leading to substantial variations in degradation activity. Therefore, the development of linker systems with modular tunability and high structural expandability has become an important direction in PROTAC optimization. The MCE Alkyne PROTAC Linker Library contains 231 linkers based on terminal and internal alkyne scaffolds, forming a highly derivatizable linker module system. These linkers serve as standardized building blocks for rapid assembly and iterative optimization of PROTAC molecules, and support efficient conjugation with azide-containing functional groups via click chemistry. In practical drug development, this type of structure not only facilitates the construction of diverse linker space libraries, accelerating lead compound screening, but also enables systematic tuning of molecular geometry and physicochemical properties, thereby improving ternary complex stability and targeted protein degradation efficiency.
97
HY-L918 Molecular Glue-like Compound Library
Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms. Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases. Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

Focused and target libraries

97
HY-L919 MCE CNS BBB Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Focused and target libraries

97
HY-L920 CNS MPO Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.

Focused and target libraries

97
HY-L922 Good ADMET Diversity Library
A diverse compound library with favorable ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) is crucial in drug discovery. Early evaluation of ADMET properties allows for the exclusion of molecules with unfavorable profiles at the initial stages, thereby reducing the risk of late-stage development failures, lowering R&D costs, and accelerating optimization of lead compounds. Based on predictions from ADMET-related AI algorithms, the compounds in this library are predicted to exhibit favorable oral bioavailability (F > 30%), reasonable plasma protein binding (PPB < 98%), minimized CYP3A4 inhibition potential (inhibition probability < 50%, CYP3A4 is the most critical drug-metabolizing enzyme in the cytochrome P450 family) , low toxicity profiles, with 140 potentially toxic substructures pre-identified and excluded via substructure searching to eliminate compounds containing hazardous fragments. The diversity library enables broad applicability in high-throughput screening (HTS) and high-content screening (HCS).

Distinctive Diversity Libraries

97
HY-L934 CRBN Ligand Library
CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein. These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins. MCE compiles 122 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.

Featured Fragment Libraries

97
HY-L935 Molecular Glue POI binding Fragment library
POI (Protein of Interest) refers to the target protein, namely the disease-causing protein or key functional protein that undergoes degradation or functional modulation in molecular glue-mediated processes. The Molecular Glue POI Library consists of a series of fragments that can specifically bind to different types of POIs. As key components of molecular glues, these ligands form stable interactions with target proteins, laying the foundation for molecular glues to induce the interaction between POIs and E3 ubiquitin ligases. The covered POIs include various types such as cancer-associated GSPT1, androgen receptors, and abnormally aggregated proteins linked to neurodegenerative diseases. This fragment library can be applied to the screening and optimization of targeted protein degraders. By screening ligands with high affinity and strong selectivity for specific POIs from the library, core structures can be identified to develop novel molecular glues. For instance, optimization of ligands targeting GSPT1 has yielded molecular glue degraders with enhanced degradation activity. Since many POIs are difficult to drug due to the lack of traditional small-molecule binding pockets, some ligands in the POI Ligand Library can modulate such POIs by inducing protein-protein interactions, thereby further expanding the scope of drug discovery for undruggable targets. MCE has compiled a POI Fragment Library comprising thousands of POI fragments with molecular weights ranging from 150 to 400. This compound library can be widely applied in Molecular Glue research and development.

Featured Fragment Libraries

97
HY-107202 Polyinosinic-polycytidylic acid
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
RIG-I-like receptor (RLR)   Toll-like Receptor (TLR)   PKD   HSP   Bcl-2 Family   Interleukin Related   Apoptosis  
Infection   Digestive System Disease   Prostate Cancer   Pain   Digestive System Inflammation   Lung Fibrosis   Rheumatoid Arthritis  
75
HY-10211 Tanespimycin
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.
HSP   Autophagy   Mitophagy   Bacterial   Apoptosis   Antibiotic  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Bacterial Infection   Digestive System Inflammation  
72
HY-18234A Leupeptin hemisulfate
Leupeptin hemisulfate is a broad-spectrum protease inhibitor. By inhibiting the activation of the PTEN/PI3K/Akt/NF-κB/ERK1/2/p38 signaling pathway, Leupeptin hemisulfate significantly reduces LPS-induced NO and ROS production, mitochondrial membrane potential hyperpolarization, phagocytic activity, pro-inflammatory cytokine release, and M1 polarization in mouse peritoneal macrophages, and reverses autophagic flux impairment. It also decreases Concanavalin A (HY-P2149)-induced proliferation index of mouse splenic lymphocytes and the Th1/IL-10 and Th2/IL-10 cytokine ratios, thereby modulating innate and adaptive immune responses. Leupeptin hemisulfate inhibits blood coagulation and tumorigenesis in mouse skin. Leupeptin hemisulfate can be used in research on chronic inflammatory diseases and skin tumorigenesis.

Source: Streptomyces roseus MB-26-AI

Ser/Thr Protease   Cathepsin   Autophagy   SARS-CoV   Atg8/LC3   NO Synthase   COX   p62   Arginase   PTEN   NF-κB   PI3K   Akt   p38 MAPK   ERK   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Respiratory Disease   Coronavirus Infection   Skin Disease  
70
HY-Y1269I Ammonium chloride, United States Pharmacopeia (USP) Reference Standard
Ammonium chloride United States Pharmacopeia (USP) Reference Standard (Salmiac, Pharmaceutical primary standard, USP) is a reagent that can be used in cell culture to provide a source of nitrogen. Ammonium chloride can be used as a heteropolar compound to regulate pH value, which can cause intracellular alkalination and metabolic acidosis, thus affecting the activity of enzymes and affecting the process of biological systems. Ammonium chloride is also a lysosome inhibitor.
Biochemical Assay Reagents   Autophagy  
Cancer  
64
HY-Y1269C Ammonium chloride, for cell culture
Ammonium chloride, for cell culture (Salmiac, for cell culture) is a reagent that can be used in cell culture to provide a source of nitrogen. Ammonium chloride can be used as a heteropolar compound to regulate pH value, which can cause intracellular alkalination and metabolic acidosis, thus affecting the activity of enzymes and affecting the process of biological systems. Ammonium chloride acts as an autophagy inhibitor.Ammonium chloride is also a lysosome inhibitor.
Environmental Pollutants   Autophagy   Biochemical Assay Reagents  
Cancer   Infection  
64
HY-Y1269 Ammonium chloride, AR, 99.5%
Ammonium chloride, as a heteropolar compound with pH value regulation, can cause intracellular alkalization and metabolic acidosis thus effecting enzymatic activity and influencing the process of biological system. Ammonium chloride is an autophagy inhibitor. Ammonium chloride is also a lysosome inhibitor.
Environmental Pollutants   Autophagy  
Cancer   Infection  
64
HY-10941 VER-155008
VER-155008 is an inhibitor of Hsp70, with IC50s of 0.5 μM, 2.6 μM, and 2.6 μM for Hsp70, Hsc70 and Grp7, respectively, and with a Kd of 0.3 μM for Hsp70.
HSP   Autophagy  
Cancer   Neurological, Eye or Ear Disease  
54
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
51
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
51
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
51
HY-15205 Ganetespib
Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3.
HSP   Apoptosis  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
49
HY-K0511A RT Master Mix for qPCR II (gDNA digester plus)

MCE RT Master Mix for qPCR II is a convenient, ready-to-use formulation for reverse transcription and can eliminate genomic DNA (gDNA) contaminations in RNA samples. With updated reverse transcriptase, this kit can synthesize cDNA more rapidly, more specifically. The 100 rxns is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Molecular Biology RT-PCR Reverse transcription PCR

45
HY-N0293 Paeoniflorin
Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity.
HSP  
Cancer   Infection   Parkinson's Disease  
44
HY-K0511 RT Master Mix for qPCR (gDNA digester plus)

MCE RT Master Mix for qPCR (gDNA digester plus) is a convenient, ready-to-use formulation for reverse transcription and can eliminate genomic DNA (gDNA) contaminations in RNA samples. The cDNA product can be directly applied as a template in a standard PCR and real time quantitative PCR (qPCR). The 100 rxns is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Molecular Biology RT-PCR Reverse transcription PCR

40
HY-13687A IKK 16 hydrochloride
IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
IKK   LRRK2   P-glycoprotein   PKD   NF-κB   TNF Receptor   Interleukin Related  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
32
HY-13687 IKK 16
IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
IKK   LRRK2   P-glycoprotein   PKD   NF-κB   TNF Receptor   Interleukin Related  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
32
HY-N0485 Liensinine Diperchlorate
Liensinine Diperchlor​ate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlor​ate inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlor​ate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.
Autophagy   Mitophagy  
Cancer   Digestive System Disease   Digestive System Inflammation   Cardiovascular Disease   Lung Fibrosis  
23
HY-111557 YM-254890
YM-254890 is a selective Gαq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y1 signal transduction pathway, with an IC50 value below 0.6 μM.

Source: the culture broth of Chromobacterium sp

P2Y Receptor  
Blood or Cardio-cerebrovascular Disease  
20
HY-B0228 Adenosine
Adenosine (Adenine riboside), a ubiquitous and BBB-permeable endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Environmental Pollutants   Endogenous Metabolite   Nucleoside Antimetabolite/Analog   Autophagy   Apoptosis  
Metabolic or Endocrine Disease   Triple-Negative Breast Cancer  
19
HY-143218 TPE-MI
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
Huntingtin   Parasite  
Plasmodium Infection   Huntington's Disease  
18
HY-D1300 LysoTracker Red
LysoTracker Red is a Red fluorescently labeled lysosomal probe with a maximum excitation/emission wavelength of 577/590 nm. The structure is composed of a fluorescein group and linked weak bases, which can freely cross the cell membrane and gather on spherical organelles. It is suitable for observing the internal biosynthesis and related pathogenesis of lysosomes.
Biochemical Assay Reagents   Fluorescent Dye  
18
HY-100411 MLi-2
MLi-2, a chemical probe, is an orally active and highly selective LRRK2 inhibitor with an IC50 of 0.76 nM. MLi-2 has the potential for Parkinson’s disease.
LRRK2  
Parkinson's Disease  
17
HY-19332 Kifunensine
Kifunensine, a potent and selective inhibitor of class I α-mannosidases isolated from Actinomycete, prevents α-mannosidases I from trimming mannose residues on glycoproteins. Kifunensine inhibits ERAD.

Source: actinomycete

Glycosidase  
Inflammation or Immune System Disease  
17
HY-B0298A Clemastine fumarate
Clemastine (HS-592; Meclastine) fumarate is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine fumarate also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine fumarate exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation .
Histamine Receptor   Pyroptosis   Autophagy   mAChR   p62   IKK   Apoptosis   Keap1-Nrf2   mTOR  
Parkinson's Disease   Obesity  
15
HY-B0089 Acarbose
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.

Source: Actinoplanes sp

Glycosidase  
Cancer   Glucose Metabolism   SARS-CoV-2 Infection  
15
HY-15594A Phen-DC3 Trifluoromethanesulfonate
Phen-DC3 Trifluoromethanesulfonate is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 Trifluoromethanesulfonate selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 Trifluoromethanesulfonate also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 Trifluoromethanesulfonate can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury.
G-quadruplex   α-synuclein   RIP kinase  
Neurodegenerative Disease   Sepsis  
13
HY-100944 Conduritol B epoxide
Conduritol B epoxide is an irreversible covalently bound acid β-glucosidase (GCase) inhibitor.
Glycosidase  
Neurological, Eye or Ear Disease  
13
HY-108535 HEPES sodium
HEPES sodium, a nonvolatile zwitterionic chemical buffering agent, is broadly applied in cell culture. HEPES sodium is effective at pH 6.8 to 8.2. HEPES sodium is also a potent inducer of lysosome biogenesis.
Biochemical Assay Reagents  
12
HY-D0199 Adenosine 5'-diphosphate disodium
Adenosine 5'-diphosphate disodium is a nucleoside diphosphate. Adenosine 5'-diphosphate disodium is the product of ATP dephosphorylation by ATPases. Adenosine 5'-diphosphate disodium is a platelet aggregation agent for hemostasis and the development and extension of arterial thrombosis.
Endogenous Metabolite  
Cardiovascular Disease  
12
HY-153169 6PPD-Q
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders.
α-synuclein   Environmental Pollutants  
Parkinson's Disease  
12
HY-N0057 3,4-Dicaffeoylquinic acid
3,4-Dicaffeoylquinic acid (3,4-Di-O-caffeoylquinic acid), naturally isolated from Laggera alata, has antioxidative, DNA protective, neuroprotective and hepatoprotective properties. 3,4-Dicaffeoylquinic acid exerts apoptosis-mediated cytotoxicity and α-glucosidase inhibitory effects. 3,4-Dicaffeoylquinic acid possesses a unique mechanism of anti-influenza viral activity, that is, enhancing viral clearance by increasing TRAIL.
Free Radical Scavengers   Glycosidase   Influenza Virus   Apoptosis   Endogenous Metabolite  
Cancer   Digestive System Disease   Digestive System Inflammation   Influenza Virus Infection   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease  
10
HY-P1098B Ac2-26 ammonium
Ac2-26 ammonium is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 ammonium induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ammonium ameliorates lung ischemia-reperfusion injury. Ac2-26 ammonium also inhibits airway inflammation and hyperresponsiveness in an asthma rat model.
IKK  
Inflammation or Immune System Disease  
9
HY-P1098A Ac2-26 TFA
Ac2-26 TFA is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model.
Annexin A   NF-κB  
Inflammation or Immune System Disease  
9
HY-10875 LRRK2-IN-1
LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
LRRK2   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Parkinson's Disease  
9
HY-P1098 Ac2-26
Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA). Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model.
Annexin A   NF-κB  
Inflammation or Immune System Disease  
9
HY-132179 Fucoidan
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities.
Glycosidase  
Cancer   Metabolic or Endocrine Disease   Cardiovascular Disease  
9
HY-12477 PF-06447475
PF-06447475 is a highly potent, selective and brain penetrant LRRK2 inhibitor with an IC50 of 3 nM.
LRRK2  
Parkinson's Disease  
8
HY-N0901A Corynoxine B
Corynoxine B is an alkaloid-based autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice.
α-synuclein  
Cancer   Parkinson's Disease  
7
HY-112904 XRK3F2
XRK3F2 is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma.
p62   Autophagy  
Leukemia/Lymphoma/Myeloma  
7
HY-18163 GNE-7915
GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM.
LRRK2  
Parkinson's Disease  
6
HY-19948 Leucomethylene blue mesylate
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (Ki of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes.
Tau Protein  
Neurological, Eye or Ear Disease  
6
HY-N7560 Safranal
Safranal is an orally active main component of Saffron (Crocus sativus) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research.
Keap1-Nrf2  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
6
HY-115576 P62-mediated mitophagy inducer
P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway. P62-mediated mitophagy inducer serves as a pharmacological tool to study the molecular mechanisms of mitosis, avoiding toxicity and some of the non-specific effects associated with the sudden dissipation of mitochondria lacking membrane potential.
p62   Mitosis   Autophagy   Mitophagy  
Cancer   Neurological, Eye or Ear Disease   Digestive System Disease   Digestive System Inflammation  
6
HY-100898 OGT 2115
OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity.
Glycosidase  
Breast Cancer  
6
HY-15934 X-GAL
X-GAL (BCIG) is a widely used chromogenic β-galactosidase substrate. X-GAL is a colorless compound until cleaved by β-galactosidase, at which point X-GAL turns to an insoluble and detectable blue compound, making X-GAL particularly useful in techniques such as blue-white screening for cloning in bacteria. X-GAL can also be used for detection of β-galactosidase activity.
Fluorescent Dye   Glycosidase  
6
HY-D2449 DQ-BSA-RED
DQ-BSA-Red is a bovine serum albumin labeled with a red fluorescent dye that can be used to detect lysosomal activity. The excitation wavelength and emission wavelength of DQ-BSA-Red are 590 nm and 620 nm, respectively. The BSA molecule in DQ-BSA-Red is labeled with high concentration of red fluorescent dye in multiple sites, which shows high fluorescence self-inhibition. Once DQ-BSA-RED enters the lysosome, DQ-BSA is cleaved by lysosomal proteases, resulting in unquenched and released fluorescent fragments, emitting bright fluorescence. Inactivated lysosomes are unable to degrade the BSA protein and thus have a lower or even no fluorescent signal.
Fluorescent Dye  
5
HY-N0901B Corynoxine hydrochloride
Corynoxine hydrochloride, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria macrophylla. Corynoxine hydrochloride is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway.
Autophagy  
Cancer   Neurological, Eye or Ear Disease  
4
HY-N0242 Fraxinellone
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Obesity  
4
HY-N0901 Corynoxine
Corynoxine, a tetracyclic oxindole alkaloid, is isolated from the hooks of Uncaria rhynchophylla. Corynoxine is a natural autophagy enhancer that promotes the clearance of alpha-synuclein via Akt/mTOR pathway.
Autophagy  
Cancer   Neurological, Eye or Ear Disease  
4
HY-13237 GSK2578215A
GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC50s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.
LRRK2   Autophagy   Mitophagy  
Cancer   Digestive System Disease   Digestive System Inflammation   Parkinson's Disease  
4
HY-N1501 Beta-asarone
Beta-asarone is an orally active and BBB-penetrable anti-inflammatory agent and neuroprotective agent, which is the major ingredient of Acorus tatarinowii Schott. Beta-asarone can protect nerve cells from apoptosis and autophagy, inhibit expression of α-synuclein, as well as myocardial protection. Beta-asarone can be used in the study of neurological and cardiovascular diseases.
α-synuclein  
Inflammation or Immune System Disease   Cardiovascular Disease   Alzheimer's Disease   Parkinson's Disease  
4
HY-N0743 Senkyunolide A
Senkyunolide A is a phthalide, anti-tumor cell proliferation agent with anticancer activity. Senkyunolide A protects neurons from corticosterone (HY-B1618)-induced apoptosis by decreasing protein phosphatase PP2A and α-synuclein phosphorylation and protein level. Senkyunolide A also inhibits osteoarthritis through the NLRP3 signaling pathway and suppresses the expression of CD137, a diagnostic biomarker for atherosclerosis.
α-synuclein  
Cancer   Inflammation or Immune System Disease   Depression   Parkinson's Disease  
4
HY-N6769 Radicicol
Radicicol is an inhibitor of Hsp90 with an IC50 value < 1 μM, and leads to proteasomal degradation. Radicicol exhibits inhibition on PDK with IC50s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB. Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC50 value of 16.04 μM.

Source: Penicillium meleagrinum

HSP   Bacterial   Antibiotic   Parasite  
Infection  
4
HY-W020033 Lanosterol
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases.
Endogenous Metabolite  
Alzheimer's Disease   Parkinson's Disease  
4
HY-P3414 Proteasome-activating peptide 1
Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis.
Proteasome  
Neurological, Eye or Ear Disease  
3
HY-138540 1-Dodecylimidazole
1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm. 1-Dodecylimidazole has hypocholesterolaemic activity and broad-spectrum antifungal activity.
Fungal  
Cancer   Fungal Infection  
3
HY-P3414A Proteasome-activating peptide 1 TFA
Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis.
Proteasome  
Neurological, Eye or Ear Disease  
3
HY-D2119 CQ-Lyso
CQ-Lyso is a lysosome-targeting chromenoquinoline. CQ-Lyso is a fluorescent probe for measuring the pH of lysosomes in living cells using only single wavelength excitation. CQ-Lyso can visualize the dynamic pH changes in lysosomes.
Fluorescent Dye  
Cancer  
3
HY-N2532 Diphyllin
Diphyllin is an orally active V-ATPase inhibitor (IC50=17 nM) and HIV-1 inhibitor (IC50=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC50=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption.
VSV   HIV   Proton Pump   Influenza Virus  
Cancer   Inflammation or Immune System Disease   Viral Infection  
3
HY-15796 GNE0877
GNE0877 is a highly selective, orally active and brain-penetrant LRRK2 inhibitor with an IC50 of 3 nM and a Ki of 0.7 nM. GNE0877 can be used for the research of neuroscience.
LRRK2  
Neurological, Eye or Ear Disease  
3
HY-P70577 SNCA Protein, Human
SNCA Protein is a protein abnormally aggregated to form Lewy bodies. SNCA Protein causes neuronal differentiation and maturation disorders, inhibits neurite outgrowth, reduces neuronal electrical activity through increased gene copy number (such as triploidy) or mutation, and promotes the release of extracellular toxic particles (such as oligomers) by interfering with the autophagy-lysosomal pathway (ALP), thereby inducing inflammatory responses and damage to neighboring cells. SNCA Protein, Human is a recombinant SNCA protein expressed by E. coli without a tag.

Species: Human; Source: E. coli

3
HY-D0914A Fast green FCF free acid
Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
α-synuclein  
Neurological, Eye or Ear Disease  
2
HY-P99123A Anti-Mouse CD28 (LALA-PG) Antibody (D665)
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Species: Mouse

CD28  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
2
HY-N5077 Sinapine
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Cholinesterase (ChE)   P-glycoprotein  
Inflammation or Immune System Disease   Ovarian Cancer   Alzheimer's Disease   Parkinson's Disease  
2
HY-W010201 Citronellol
Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis.
p62   Environmental Pollutants   Fungal   Atg8/LC3   PI3K   Autophagy   ERK   Apoptosis   Necroptosis   Reactive Oxygen Species (ROS)   TNF Receptor  
Respiratory Disease   Breast Cancer   Pancreatic Cancer   Fungal Infection   Pain   Autoimmune Disease   Digestive System Inflammation   Cardiovascular Disease   Non-Small Cell Lung Cancer   Parkinson's Disease  
2
HY-129960 L-Selenocystine
L-Selenocystine is a selenium-containing amino acid. L-Selenocystine has redox properties. L-Selenocystine is cytotoxic to various tumor cells and can induce the production of ROS and apoptosis. L-Selenocystine can block the Nrf2 and autophagy pathways. L-Selenocystine has anti-tumor activity.
Keap1-Nrf2   Autophagy   p62   Apoptosis   Reactive Oxygen Species (ROS)   Caspase   Bcl-2 Family  
Inflammation or Immune System Disease  
2
HY-W018791 Bifendate
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR).
HBV   Autophagy   Cytochrome P450   Atg8/LC3   p62   P-glycoprotein  
Ovarian Cancer   Viral Infection   Cardiovascular Disease  
2
HY-P99644 ACT017
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.

Species: Human

Glycoprotein VI  
Blood or Cardio-cerebrovascular Disease  
2
HY-D0914 Fast Green FCF
Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
Environmental Pollutants   α-synuclein  
Neurological, Eye or Ear Disease  
2
HY-112624 Dextran
Dextran (Dextran 40) has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Bacterial  
Cancer   Blood or Cardio-cerebrovascular Disease  
2
HY-P2929 PNGase F
PNGase F, a glycosidase, catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. PNGase F removes nearly all N-linked oligosaccharides from glycoproteins. PNGase F can release N-glycans from glycoproteins in glycoanalytical workflows.

Species: Elizabethkingia miricola

Biochemical Assay Reagents   Glycosidase  
Cancer  
2
HY-P80899 SQSTM1/p62 Antibody (YA062)
SQSTM1/p62 Antibody (YA062) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SQSTM1/p62.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-P80208 LAMP2 Antibody (YA309)
LAMP2 Antibody (YA309) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LAMP2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-W040146S Propionylpromazine-d6 hydrochloride
Propionylpromazine-d6 (hydrochloride) is the deuterium labeled Propionylpromazine hydrochloride. Propionylpromazine hydrochloride (Propiopromazine hydrochloride), a dopamine receptor D2 (DRD2) antagonist, can be used in the research of Parkinson disease.
Dopamine Receptor  
Neurological, Eye or Ear Disease  
1
HY-N1983 Caudatin
Caudatin is an orally active and brain-penetrant C-21 steroidal found in Cynanchum bungei decne with a variety of biological activities. Caudatin can inhibit cell proliferation, migration, invasion, cause cell phase arrest, induce apoptosis, autophagy, ROS prodution and loss of mitochondrial membrane potential. Caudatin activates PARP, caspase-3, -7, -9, upregulates pro-apoptotic Bad and Bax and downregulates anti-apoptotic Bcl-2 and Bcl-XL. Caudatin suppresses VEGF, FAK phosphorylation, upregulates p21, p27, DR5 protein expression, activates the p38 MAPK, JNK and PPARα/TFEB-mediated autophagy-lysosomal signaling pathways. Caudatin can be used for the research of cancer, inflammation and neurological disease, such as glioma and Alzheimer's disease.
Apoptosis   Autophagy   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   PARP   Caspase   Bcl-2 Family   VEGFR   FAK   WDR5   p38 MAPK   JNK   PPAR  
Inflammation or Immune System Disease   Glioma   Alzheimer's Disease  
1
HY-N2339 Cholesteryl behenate
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.
Endogenous Metabolite  
Metabolic or Endocrine Disease  
1
HY-D0857S HEPES-d18
HEPES-d18 is the deuterium labeled HEPES. HEPES, a nonvolatile zwitterionic chemical buffering agent, is broadly applied in cell culture. HEPES is effective at pH 6.8 to 8.2. HEPES is also a potent inducer of lysosome biogenesis.
Isotope-Labeled Compounds  
1
HY-N6929 Angelic acid
Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity.
Ferroptosis   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease   Parkinson's Disease  
1
HY-N1458 Isoschaftoside
Isoschaftoside, a C-glycosylflavonoid from Desmodium uncinatum root exudate, can inhibit the growth of germinated S. hermonthica radicles. Isoschaftoside reduces reactive oxygen species (ROS) and induces proliferation in senescent cells. Isoschaftoside activates autophagy. Isoschaftoside can be used for anti-tumor, anti-inflammatory, antioxidant, antihypertensive, hepatoprotective and nematicidal study.
Parasite   Autophagy   p62   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Parasitic Infection   Hypertension  
1
HY-P99253 Mogamulizumab
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).

Species: Human

CCR  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
1
HY-D1445 LysoSensor PDMPO
PDMPO, a lysosome pH indicator, is an excellent fluorescent acidotropic reagent for fluorescence imaging. PDMPO is a potent tool with which to study acidic organelles of live cells. PDMPO exhibits pH-dependent dual-excitation and dual-emission spectral peaks. PDMPO produces a blue fluorescence in weakly acidic organelles and shifts to yellow in more acidic lysosomes. (Abs=329 nm; Em=440/540 nm).
Fluorescent Dye  
Metabolic or Endocrine Disease  
1
HY-107811 Harmol
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model.
Autophagy   Monoamine Oxidase   Apoptosis   α-synuclein   Mitosis  
Cancer   Digestive System Disease   Depression   Digestive System Inflammation   Parkinson's Disease  
1
HY-111126 K67
K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2.
p62   Keap1-Nrf2  
Colorectal Cancer   Liver Cancer   Ovarian Cancer  
1
HY-148030 XL01126
XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC50: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease.
LRRK2   PROTACs   Mitophagy  
Parkinson's Disease  
1
HY-P2802 α-Glucosidase, Yeast
α-Glucosidase, Yeast (α-D-Glucosidase, Yeast), a carbohydrate hydrolyzing enzyme, catalyzes the liberation of α-glucose from the non-reducing end of the substrate. α-Glucosidase can facilitate the absorption of glucose by the small intestine. Inhibition of α-Glucosidase is an effective management of non-insulin-dependent diabetes mellitus (NIDDM).
Glycosidase  
Metabolic or Endocrine Disease  
1
HY-145934 UDP-GalNAz disodium
UDP-GalNAz (UDP-N-azidoacetylgalactosamine) disodium is the analogue of UDP-GalNAc disodium (HY-114365). UDP-GalNAc disodium is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GalNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GalNAz disodium is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Biochemical Assay Reagents   OGT   Glycosidase  
Metabolic or Endocrine Disease  
1
HY-P71327 SNCA Protein, Human (His)
Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA Protein, Human (His) is the recombinant human-derived SNCA protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

1
HY-P72525 LAMP2/CD107b Protein, Human (HEK293, His)
LAMP2 is a key lysosomal glycoprotein that plays crucial roles in lysosomal biogenesis, pH regulation, and autophagy. It directly inhibits the TMEM175 proton channel, optimizing lysosomal acidity for efficient hydrolase activity. LAMP2/CD107b Protein, Human (HEK293, His) is the recombinant human-derived LAMP2/CD107b protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Human; Source: HEK293

CD Antigens NK Cell CD Proteins Monocyte CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-2/CD107b

1
HY-P74653 PARK7/DJ-1 Protein, Human (His)
The multifunctional PARK7/DJ-1 protein plays a key role in cellular defense against oxidative stress and cell death. It acts as an oxidative stress sensor, redox-sensitive chaperone and protease, and participates in neuroprotective mechanisms by stabilizing NFE2L2 and PINK1 proteins. PARK7/DJ-1 Protein, Human (His) is the recombinant human-derived PARK7/DJ-1 protein, expressed by E. coli , with C-His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

1
HY-P71625 PARK7/DJ-1 Protein, Human (GST)
The multifunctional PARK7/DJ-1 protein plays a key role in cellular defense against oxidative stress and cell death. It acts as an oxidative stress sensor, redox-sensitive chaperone and protease, and participates in neuroprotective mechanisms by stabilizing NFE2L2 and PINK1 proteins. PARK7/DJ-1 Protein, Human (GST) is the recombinant human-derived PARK7/DJ-1 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Hydrolases (EC 3)

1
HY-P80206 LAMP1 Antibody (YA311)
LAMP1 Antibody (YA311) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LAMP1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-P80518 SQSTM1/p62 Antibody (YA669)
SQSTM1/p62 Antibody (YA669) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SQSTM1/p62.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

1
HY-P82328 alpha Synuclein Antibody (YA2073)
alpha Synuclein Antibody (YA2073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

1
HY-N0698R Crocin II (Standard)
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.
Reference Standards   Endogenous Metabolite   α-synuclein  
Cancer   Neurological, Eye or Ear Disease  
/
HY-14397S1 Indomethacin-d4 Methyl Ester
Indomethacin-d4 Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes.
COX   Autophagy  
Cancer   Inflammation or Immune System Disease  
/
HY-P992449 REGN2878
REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (KD) of 1.05 nM and an IC50 of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001.

Species: Human

ADC Antibodies  
Breast Cancer   Prostate Cancer  
/
HY-P5277 TAT-GluN2BCTM
TAT-GluN2BCTM is a membrane-permeable DAPK1-targeting peptide. TAT-GluN2BCTM targets active DAPK1 to lysosomes for degradation. TAT-GluN2BCTM protects neurons from oxidative stress and NMDAR-mediated excitotoxicity by knocking down DAPK1. TAT-GluN2BCTM can be used in the study of neuroprotection.
DAPK  
Neurological, Eye or Ear Disease  
/
HY-P991234 COVA208
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer.

Species: Human

EGFR   p38 MAPK   PI3K   Akt  
Cancer  
/
HY-D2321 Lyso Flipper-TR 29
Lyso Flipper-TR 29 is a Flipper probe that can label lysosomes. Lyso Flipper-TR 29 enters lysosomes and late endosomes by transient deprotonation to cross their membranes in neutral form.
Fluorescent Dye  
/
HY-D2971 NCIC-VIS
NCIC-VIS is a lysosome-targeted, viscosity-sensitive two-photon near-infrared fluorescent probe. NCIC-VIS has a rigid structure that can restrict molecular torsion, thereby increasing the fluorescence quantum yield and two-photon absorption cross-section. NCIC-VIS enables real-time imaging of the autophagy process in cells.
Fluorescent Dye   Autophagy  
/
HY-N10332 Leptosphaerodione
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent.

Source: Remotididymella sp.

Proteasome  
Cancer  
/
HY-P5044 α-Synuclein (45-54) (human)
α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-N10283 Neoechinulin C
Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model.

Source: Aspergillus niveoglaucus

Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P5041 α-Synuclein (34-45) (human)
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker.
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P11080 Oncocin
Oncocin is an antibacterial peptide. It belongs to proline-rich antimicrobial peptides (PrAMPs). Oncocin works against Gram-negative bacteria. It has MIC values of 0.125-8 μg/mL for 34 strains and clinical isolates of Enterobacteriaceae and nonfermenters. Oncocin binds to the substrate-binding domain of the chaperone DnaK. The binding has dissociation constants in the micromolar range. This binding causes protein misfolding and aggregation and the bacteria death.
Bacterial  
Infection  
/
HY-W014632S 4-Trifluoromethylsalicylic acid-13C6
4-Trifluoromethylsalicylic acid-13C6 is the 13C labeled 4-Trifluoromethylsalicylic acid. 4-Trifluoromethylsalicylic acid is a platelet aggregation inhibitor.
Isotope-Labeled Compounds  
/
HY-P992032 TPP-9476
TPP-9476 (BAY-943 antibody) is an anti-human IL3RA (CD123) monoclonal antibody with human IL3RA Kd of 11 nM and cynomolgus monkey IL3RA Kd of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models.

Species: Human

Interleukin Related  
Acute Myeloid Leukemia   Hodgkin Lymphoma  
/
HY-N10306 Sycosterol A
Sycosterol A is a sterol-based α-synuclein (α-syn) inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases.

Source: Australian Ascidian Sycozoa cerebriformis

α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-N12434 Euphorblin R
Euphorblin R (EOF2) is a rhamnyl diterpenoid isolated from Euphorbia resinifera. Euphorblin R may promote lysosomal biogenesis and has the potential to be used in the study of lysosome-related diseases.
Others  
Metabolic or Endocrine Disease  
/
HY-P5046 α-Synuclein (71-82) (human)
α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-121252S Dopal-d5
Dopal-d5 is the deuterium labeled Dopal (HY-121252). Dopal is a metabolite and aldehyde neurotoxin of Dopamine (HY-B0451). Dopal exhibits cytotoxicity, induces α-synuclein oligomerization and aggregation, and is closely associated with the pathogenesis of Parkinson's disease. Dopal can be used in research related to Parkinson's disease.
Isotope-Labeled Compounds   α-synuclein   Apoptosis   Drug Metabolite  
Neurological, Eye or Ear Disease  
/
HY-13720AS Pergolide-d7 mesylate
Pergolide-d7 (mesylate) is the deuterium labeled Pergolide mesylate. Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research.
Isotope-Labeled Compounds   Dopamine Receptor  
Neurological, Eye or Ear Disease  
/
HY-W740650 Migalastat hydrochloride-15N
Migalastat hydrochloride-15N (GR181413A-15N) is the 15N-labeled Migalastat hydrochloride (HY-14929A). Migalastat (GR181413A free base) hydrochloride is an orally active α-galactosidase A molecular chaperone, with an IC50 value of 0.04 μM for human α-Gal A. Migalastat binds to the active site of certain unstable mutant forms of α-galactosidase A, facilitating their transport to the lysosome. After dissociation in the acidic environment, Migalastat enables the mutant α-galactosidase A to exhibit biological activity.
Isotope-Labeled Compounds   Glycosidase  
/
HY-W707693 Scyllo-Inositol-d6
Scyllo-Inositol-d6 is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
Isotope-Labeled Compounds   α-synuclein   Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-D3222 NIR-PN1
NIR-PN1 is a blood-brain barrier-permeable near-infrared fluorescent indicator targeting peroxynitrite anion (ONOO−) (Ex/Em = 510 nm/670 nm). NIR-PN1 reacts with ONOO− to trigger a strong near-infrared fluorescence enhancement, enabling the detection of ONOO− flux. NIR-PN1 allows the imaging of ONOO− flux in various Parkinson's disease models. NIR-PN1 is applicable to Parkinson's disease-related research.
Fluorescent Dye  
Parkinson's Disease  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-173418 Carbaprostacyclin-biotin
Carbaprostacyclin-biotin (cPGI-biotin; Carbacyclin-biotin) is a biotin-bound Carbacyclin (Carbaprostacyclin) (HY-112322). Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
Prostaglandin Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-DY1024 TPE-MI (solution)
TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
Solvent and concentration: DMSO: 10 mM
Huntingtin   Parasite  
/
HY-N0901AR Corynoxine B (Standard)
Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice.
α-synuclein   Reference Standards  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P10360 Tat-βsyn-degron
Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders.
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-N2991R Dehydropachymic acid (Standard)
Dehydropachymic acid (Standard) is the analytical standard of Dehydropachymic acid. This product is intended for research and analytical applications. Dehydropachymic acid is one of the major triterpenes isolated from Poria cocos. Dehydropachymic acid is more effective in autophagy-lysosome pathway (ALP) impaired cells rather than normal cells.
Reference Standards   Autophagy  
Neurological, Eye or Ear Disease  
/
HY-135447 BM-531
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED100 of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED50 of 0.482 μM. BM-531 inhibits high-K+-induced contraction of porcine uterine smooth muscle.
Prostaglandin Receptor  
/
HY-P5040 Cbz-Pro-Leu-Gly-OH
Cbz-Pro-Leu-Gly-OH is a tripeptide that can be used in Parkinson's disease research.
Others  
Neurological, Eye or Ear Disease  
/
HY-P992382 IC 100
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003.

Species: Human

Interleukin Related  
Multiple Sclerosis  
/
HY-G0017S1 N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d4 is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia.
Isotope-Labeled Compounds   Drug Metabolite   P-glycoprotein   Apoptosis  
Cancer   Parkinson's Disease  
/
HY-P991380 TXB4
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research.

Species: Human

Transferrin Receptor  
Neurological, Eye or Ear Disease  
/
HY-N0242R Fraxinellone (Standard)
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
Reference Standards   PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-122297 H-​Arg-​Phe-​OH
H-​Arg-​Phe-​OH is an amphipathic peptide. H-​Arg-​Phe-​OH has the ability to induce native-like protein aggregation. H-​Arg-​Phe-​OH can induce aggregation of the neutral model protein yeast alcohol dehydrogenase (ADH).
Others  
/
HY-180990 POI ligand-3
POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989).
Ligands for Target Protein for PROTAC   Polo-like Kinase (PLK)  
Cancer  
/
HY-P991236 MHES0488A
MHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer.

Species: Human

EGFR   DNA Alkylator/Crosslinker  
Breast Cancer  
/
HY-N15545 Thaigranatumin I
Thaigranatumin I is a limonoid compound found in the seeds of the Thai mangrove (Xylocarpus granatum). Thaigranatumin I is promising for research of neurodegenerative diseases such as Parkinson's diseases.
Drug Derivative  
Neurological, Eye or Ear Disease  
/
HY-N6929R Angelic acid (Standard)
Angelic acid (Standard)) is the analytical standard of Angelic acid (HY-N6929). This product is intended for research and analytical applications. Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity.
Reference Standards   Ferroptosis   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P10404 PDpep1.3
PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions.
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P992056 Anti-Human/Mouse LY6E Antibody (9B12)
Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8+ T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8+ T cells strictly depends on the presence of PILRα, and it does not affect CD4+ T cells or T cell development in the thymus, exhibiting high specificity.

Species: Human/Mouse

Autophagy  
Lung Cancer   Breast Cancer  
/
HY-D3224 HCP
HCP is a two-photon fluorescent probe capable of crossing the blood-brain barrier, which is specifically designed for real-time detection of hypochlorous acid (HClO/ClO-) produced by myeloperoxidase (MPO). Chlorination of the quinoline skeleton of HCP generates HCP-Cl, which eliminates intramolecular charge transfer (ICT) quenching and thereby produces fluorescence. HCP is suitable for in vivo dynamic imaging of HClO in the brains of epileptic mice and high-throughput screening of antiepileptic drugs (HCP-Cl: Ex/Em = 800 nm/495 nm).
Fluorescent Dye  
Epilepsy  
/
HY-107413G SR11237 (GMP)
SR11237 GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease.
RAR/RXR   Tyrosine Hydroxylase  
Inflammation or Immune System Disease   Parkinson's Disease   Osteoarthritis  
/
HY-D2254 CTB probe-1
CTB probe-1 (probe 1) a lysosome-targeting fluorogenic small-molecule probe for fluorescence imaging in living cells.
Fluorescent Dye  
/
HY-40178S NH2-C4-NH-Boc-d8
NH2-C4-NH-Boc-d8 is the deuterium labeled NH2-C4-NH-Boc (HY-40178). NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-13720S Pergolide-d7 hydrochloride
Pergolide-d7 hydrochloride is deuterated labeled Pergolide (HY-13720). Pergolide (LY127809 (free base)) is an ergot-derived orally active dopamine receptor agonist. Pergolide can be used for Parkinson disease research.
Dopamine Receptor   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-14929S Migalastat-d2 hydrochloride
Migalastat-d2 hydrochloride (GR181413A-d2) is the deuterium labeled Migalastat hydrochloride (HY-14929A). Migalastat (GR181413A free base) is an orally active α-galactosidase A molecular chaperone, with an IC50 value of 0.04 μM for human α-Gal A. Migalastat binds to the active site of certain unstable mutant forms of α-galactosidase A, facilitating their transport to the lysosome. After dissociation in the acidic environment, Migalastat enables the mutant α-galactosidase A to exhibit biological activity.
Isotope-Labeled Compounds   Glycosidase  
/
HY-N15554 Thaigranatumin A
Thaigranatumin A is a protolimonoid compound found in the seeds of the Thai mangrove (Xylocarpus granatum). Thaigranatumin A is promising for research of neurodegenerative diseases such as Parkinson's diseases.
Drug Derivative  
Neurological, Eye or Ear Disease  
/
HY-D1549 o-Pah
o-Pah is a BODIPY derivative with an -NH2 and -OH substituted meso-Ph group. o-Pah exhibits metal-induced J-aggregation in the presence of Cu2+ and a specific fluorescence enhancement for Hg2+ (Ex/Em=483/(495-600) nM).
Fluorescent Dye  
/
HY-N16524 Alpinin A
Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease.
α-synuclein  
Parkinson's Disease  
/
HY-P99648A Gosuranemab (powder)
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.
Tau Protein  
Alzheimer's Disease  
/
HY-B0531S Triflusal-d3
Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease.
Isotope-Labeled Compounds   COX   NF-κB   Phosphodiesterase (PDE)   NO Synthase   Prostaglandin Receptor  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Depression   SARS-CoV-2 Infection   Rheumatoid Arthritis  
/
HY-P1051 β-Amyloid (12-28)
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-W230975 (E/Z)-Piperine
(E/Z)-Piperine ((E/Z)-Bioperine) is an alkaloid with a pungent property. (E/Z)-Piperine shows anti-inflammation, immunomodulatory and anti-cancer, antispasmodic and anti-secretory effects. (E/Z)-Piperine demonstrates significant neuroprotective effect in Alzheimer’s disease and Parkinson’s disease.
Cytochrome P450   P-glycoprotein  
Inflammation or Immune System Disease   Ovarian Cancer   Alzheimer's Disease   Parkinson's Disease  
/
HY-D2204 SHP1-IN-1
SHP1-IN-1 (compound 5p) is a fluorescent probe for the protein tyrosine phosphatase SHP1 containing the Src homology 2 domain. SHP1-IN-1 has SHP1 inhibitory activity, selectivity for Fe3+ ions and good fluorescence properties. SHP1-IN-1 exhibits aggregation post-quenching (ACQ) effect, good interference immunity and low detection limit (5.55 μM).
Phosphatase   SHP1   Fluorescent Dye  
Cancer  
/
HY-P11104 SsrA tag
SsrA tag is an 11-aa peptide added to the C-terminus of proteins stalled during translation, targeting them for degradation by ClpXP and ClpAP.
Others  
/
HY-P5043 α-Synuclein (67-78) (human)
α-Synuclein (67-78) (human) is the 67-78 fragment of α-Synuclein. α-Synuclein (67-78) (human) promotes network activity drive and blocks KCl-induced syt1L-ab uptake.
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-130398 Aerophobin-2
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy.

Source: marine sponge Verongia aerophoba

α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P3140 α-Synuclein (61-75)
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P99803 Clervonafusp alfa
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research.
Glycosidase  
/
HY-W504836 Deuteroporphyrin IX dihydrochloride
Deuteroporphyrin IX (dihydrochloride) is a photosensitizer with high lipophilicity and amphiphilicity, capable of providing photosensitivity for cell membrane systems. Deuteroporphyrin IX (dihydrochloride) can induce irreversible discharge elimination in individual neurons.
Photosensitizer  
Neurological, Eye or Ear Disease  
/
HY-169235 DHHC3 ligand 1
DHHC3 degrader 1 is a PROTAC target protein ligand that is used to synthesize PCC16 chloride (HY-169232).
Ligands for Target Protein for PROTAC  
Cancer  
/
HY-P3846 (Glu20)-Amyloid β-Protein (1-42)
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N15613 α-Synuclein inhibitor 14
α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease.
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-W250795A Maltodextrin, dextrose equivalent 13.0-17.0
Maltodextrin, dextrose equivalent 13.0-17.0 can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs.
Biochemical Assay Reagents  
/
HY-N3855 Erythrabyssin II
Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer.
Autophagy   Apoptosis  
/
HY-Y0790S Cuminaldehyde-d8
Cuminaldehyde-d8 is deuterated labeled Cuminaldehyde (HY-Y0790). Cuminaldehyde is the major component of Cuminum cyminum, a natural aldehyde with inhibitory effect on alpha-synuclein fibrillation and cytotoxicity. Cuminaldehyde shows anticancer activity.
Endogenous Metabolite   Isotope-Labeled Compounds  
Cancer  
/
HY-107811R Harmol (Standard)
Harmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model.
Apoptosis   α-synuclein   Autophagy   Reference Standards   Monoamine Oxidase   Mitosis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-W856375 (E)-BSPOTPE
(E)-BSPOTPE is the E configuration of BSPOTPE (HY-W856375A). BSPOTPE binds Human serum albumin (HSA) (HY-P1956), exhibits aggregation-induced emission (AIE) phenomenon. BSPOTPE shows selectivity for albumin (such as HSA and BSA), but has no obvious fluorescence response to other proteins and DNA. BSPOTPE can be used as fluorescent probe for HSA.
MOFs   Fluorescent Dye  
/
HY-P991898 IASO-782
IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).

Species: Human

CD19  
Systemic Lupus Erythematosus  
/
HY-D2460 Dextran-CY5.5
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Fluorescent Dye  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P990793 Anti-Mouse CD28 Antibody (D665)
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Species: Mouse

CD28  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N5077R Sinapine (Standard)
Sinapine is an alkaloid isolated from seeds of the cruciferous species. Sinapine exhibits anti-inflammatory, anti-oxidant, anti-tumor, anti-angiogenic and radio-protective effects. Sinapine is also an acetylcholinesterase (AChE) inhibitor and can be used for the research of Alzheimer’s disease, ataxia, myasthenia gravis, and Parkinson’s disease.
Reference Standards   Cholinesterase (ChE)   P-glycoprotein  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-W728096 Migalastat-d5
Migalastat-d5 (GR181413A-d5 (free base)) is deuterium labeled Migalastat. Migalastat (GR181413A free base) is an orally active α-galactosidase A molecular chaperone, with an IC50 value of 0.04 μM for human α-Gal A. Migalastat binds to the active site of certain unstable mutant forms of α-galactosidase A, facilitating their transport to the lysosome. After dissociation in the acidic environment, Migalastat enables the mutant α-galactosidase A to exhibit biological activity.
Isotope-Labeled Compounds   Glycosidase  
/
HY-W779021 Adenosine-15N
Adenosine-15N (Adenine riboside-15N) is 15N labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Autophagy   Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-B0512S Sulfamerazine-d4
Sulfamerazine-d4 is a deuterium labeled Sulfamerazine. Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection.
Isotope-Labeled Compounds   Bacterial  
Infection  
/
HY-W010041R Scyllo-Inositol (Standard)
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
Reference Standards   α-synuclein   Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-P991782 Anti-Mouse CCR8 Antibody (C8Mab-2)
Anti-Mouse CCR8 Antibody (C8Mab-2) is an antibody targeting mouse CCR8. Anti-Mouse CCR8 Antibody (C8Mab-2) induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis to eliminate CCR8-expressing cells. Anti-Mouse CCR8 Antibody (C8Mab-2) eliminates regulatory T cells in the tumor microenvironment, increases CD8+ T cell infiltration and inhibits tumor growth. Anti-Mouse CCR8 Antibody (C8Mab-2) recognizes the N-terminal amino acid region 1-33 of mouse CCR8, in which Thr20 serves as the core binding epitope amino acid. Anti-Mouse CCR8 Antibody (C8Mab-2) is applicable to research related to colon cancer, breast cancer and bladder cancer.

Species: Mouse

CCR  
Inflammation or Immune System Disease   Breast Cancer   Colorectal Cancer   Bladder Cancer  
/
HY-P991834 Anti-Mouse CD41 Antibody (S-R690)
Anti-Mouse CD41 Antibody (S-R690) reacts with mouse CD41. CD41 is a crucial protein involved in platelet aggregation and hemostasis. Recommend Isotype Controls: Rat IgG1 kappa, Isotype Control (HY-P99979).

Species: Mouse

Integrin  
Cardiovascular Disease  
/
HY-167092 SD-1077
SD-1077 is a selectively deuterated precursor of dopamine (DA). SD-1077 can be used for the study of Parkinson's disease.
Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-108535R HEPES sodium (Standard)
HEPES sodium (Standard) is the analytical standard of HEPES (sodium) (HY-108535). This product is intended for research and analytical applications. HEPES sodium, a nonvolatile zwitterionic chemical buffering agent, is broadly applied in cell culture. HEPES sodium is effective at pH 6.8 to 8.2. HEPES sodium is also a potent inducer of lysosome biogenesis.
Biochemical Assay Reagents   Reference Standards  
/
HY-W040216 MEGA-9
MEGA-9 (N-Nonanoyl-N-methylglucamine) is a green, biodegradable glycosyl nonionic surfactant and micelle-forming agent. MEGA-9 acts as a membrane solubilizer, forms vesicles, solubilizes milk fat, eliminates non-specific reactions of test strips, and restores antigen-antibody reactions in cheddar cheese homogenates for the detection of staphylococcal enterotoxin B (SEB).
Biochemical Assay Reagents  
/
HY-W800775 BP Fluor 647 Alkyne
BP Fluor 647 Alkyne is a bright green-fluorescent dye optimal for use with the 633, 650 nm Argon laser. The alkyne group can react with azides via copper catalyzed Click Chemistry reactions. The dye is water soluble and pH-insensitive from pH 4 to pH 10. The dye has 4 sulfonate groups which make it highly water soluble and cause less aggregation in the aqueous solution. BP Fluor 647 Alkyne is used for protein and antibody labeling, or nucleic acid applications with high labeling density.
Fluorescent Dye  
/
HY-P10494 FEFEFKFK
FEFEFKFK is an octapeptide that self-assembles into fibrillar structures. FEFEFKFK is able to form gels at concentrations greater than about 7 mg/mL. The self-assembly and gelation properties of FEFEFKFK help to understand the mechanism of amyloid fibril formation in protein misfolding diseases such as Alzheimer's disease and Parkinson's disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-138540R 1-Dodecylimidazole (Standard)
1-Dodecylimidazole (Standard) is the analytical standard of 1-Dodecylimidazole. This product is intended for research and analytical applications. 1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm. 1-Dodecylimidazole has hypocholesterolaemic activity and broad-spectrum antifungal activity.
Fungal   Reference Standards  
Cancer  
/
HY-W777681 Triflusal-13C6
Triflusal-13C6 is a C13-labeled Triflusal. Triflusal is a platelet aggregation inhibitor.
Isotope-Labeled Compounds  
/
HY-W100287R Murrayafoline A (Standard)
Murrayafoline A (Standard) is the analytical standard of Murrayafoline A (HY-W100287). This product is intended for research and analytical applications. Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
NF-κB   Reference Standards   p38 MAPK   Interleukin Related   IKK   JNK   β-catenin   Wnt  
/
HY-B0512S1 Sulfamerazine-13C6
Sulfamerazine-13C6 (RP2632-13C6) is 13C labeled Sulfamerazine (HY-B0512). Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection.
Isotope-Labeled Compounds   Antibiotic   Bacterial  
Infection  
/
HY-W127622 NDSB 256-4T
NDSB 256-4T is a non-washing sulfabetaine compound. NDSB-256-4T prevents protein aggregation and promotes protein folding by interacting with early folding intermediates.
Biochemical Assay Reagents  
/
HY-122297A H-​Arg-​Phe-​OH TFA
H-​Arg-​Phe-​OH TFA is an amphipathic peptide. H-​Arg-​Phe-​OH TFA has the ability to induce native-like protein aggregation. H-​Arg-​Phe-​OH TFA can induce aggregation of the neutral model protein yeast alcohol dehydrogenase (ADH).
Others  
/
HY-B1018AS Phenelzine-d5 sulfate
Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer.
Isotope-Labeled Compounds   Monoamine Oxidase   GABA Receptor   Histone Demethylase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-14397S Indomethacin-d4
Indomethacin-d4 (Indometacin-d4) is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes.
Isotope-Labeled Compounds   COX   Autophagy  
Cancer   Inflammation or Immune System Disease  
/
HY-D2460A Dextran-CY5.5 (MW 10000)
Dextran-CY5.5 (MW 10000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Fluorescent Dye  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-D2002 ATTO 488 maleimide
ATTO 488 maleimide is a thiol-reactive fluorescent labeling reagent that forms a covalent bond via its maleimide group with the thiol group of the C-terminal cysteine residue of α-synGC. ATTO 488 maleimide enables α-syn fiber imaging via super-resolution stimulated emission depletion (STED) fluorescence microscopy. ATTO 488 maleimide is applicable to research related to Parkinson's disease (Ex/Em = 488/592nm).
Fluorescent Dye  
Parkinson's Disease  
/
HY-D2460B Dextran-CY5.5 (MW 40000)
Dextran-CY5.5 (MW 40000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander.
Fluorescent Dye  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P10818 Polyglutamine binding peptide 1
Polyglutamine binding peptide 1 (QBP1) is a peptide inhibitor of polyglutamine (polyQ). Polyglutamine binding peptide 1 inhibits polyQ protein aggregation in vitro and suppresses polyQ-induced cell death in cell culture.
Huntingtin  
Neurological, Eye or Ear Disease  
/
HY-P4704 α-Synuclein (61-95) (human)
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-N1983R Caudatin (Standard)
Caudatin (Standard) is the analytical standard of Caudatin (HY-N1983). This product is intended for research and analytical applications. Caudatin is an orally active and brain-penetrant C-21 steroidal found in Cynanchum bungei decne with a variety of biological activities. Caudatin can inhibit cell proliferation, migration, invasion, cause cell phase arrest, induce apoptosis, autophagy, ROS prodution and loss of mitochondrial membrane potential. Caudatin activates PARP, caspase-3, -7, -9, upregulates pro-apoptotic Bad and Bax and downregulates anti-apoptotic Bcl-2 and Bcl-XL. Caudatin suppresses VEGF, FAK phosphorylation, upregulates p21, p27, DR5 protein expression, activates the p38 MAPK, JNK and PPARα/TFEB-mediated autophagy-lysosomal signaling pathways. Caudatin can be used for the research of cancer, inflammation and neurological disease, such as glioma and Alzheimer's disease.
Reference Standards   Apoptosis   Autophagy   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   PARP   Caspase   Bcl-2 Family   VEGFR   FAK   WDR5   p38 MAPK   JNK   PPAR  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-B0228S12 Adenosine-d13
Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is deuterium labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Autophagy   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-W020033R Lanosterol (Standard)
Lanosterol (Standard) is the analytical standard of Lanosterol. This product is intended for research and analytical applications. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases[1][2].
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-N3187 Nimbin
Nimbin is an orally active intermediate limonoid found in Azadirachta. Nimbin prevents tau aggregation and increases cell viability. Nimbin is effective inhibits the envelope protein of dengue virus. Nimbin has anti-inflammatory, antipyretic, antifungal, antihistamine, antiseptic, antioxidant, anti-cancer and anti-viral properties. Nimbin is promising for research of neurodegenerative diseases and viral infections.
Flavivirus   Dengue Virus   Fungal   Bacterial   Histamine Receptor  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-173150 Hapalindole Q
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a Kd of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.).

Source: Hapalosiphon fontinalis

YAP  
Cancer  
/
HY-W800680 BP Fluor 488 DBCO
BP Fluor 488 DBCO is a popular labeling dye used in copper-free Click Chemistry reactions. It will react with the azide group in antibody, proteins, peptides, amino-modified oligos, and other target molecules. The dye has an excitation peak at 499 nm and an emission peak at 520 nm. The conjugates are widely used in microscopy, flow cytometry, and other applications. BP Fluor 488 is a pure 5-sulfonated rhodamine molecule and it eliminates the lot-to-lot variation caused by two isomers ratio differences.
Fluorescent Dye  
/
HY-Y1269AS Ammonium chloride-d4
Ammonium chloride-d4 is the deuterium labeled Ammonium chloride. Ammonium chloride, as a heteropolar compound with pH value regulation, can cause intracellular alkalization and metabolic acidosis thus effecting enzymatic activity and influencing the process of biological system. Ammonium chloride is an autophagy inhibitor. Ammonium chloride is also a lysosome inhibitor.
Isotope-Labeled Compounds   Autophagy  
Cancer  
/
HY-B0228S9 Adenosine-13C10,15N5
Adenosine-13C10,15N5 is the 13C and 15N labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Apoptosis   Nucleoside Antimetabolite/Analog   Autophagy   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-100573S Necrosulfonamide-d4
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Isotope-Labeled Compounds   Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Integrin   NO Synthase   Heme Oxygenase (HO)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-10888S Istradefylline-13C,d3
Istradefylline-13C,d3 is the 13C- and deuterium labeled Istradefylline. Istradefylline is a very potent, selective and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.
Isotope-Labeled Compounds   Adenosine Receptor  
Neurological, Eye or Ear Disease  
/
HY-P99911 Efizonerimod alfa
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma.
Orexin Receptor (OX Receptor)  
Cancer Immunology   Immunotherapy for Melanoma  
/
HY-P3140A α-Synuclein (61-75) TFA
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P99937 Elipovimab
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells

Species: Human

HIV  
Infection  
/
HY-P5082 α-Synuclein 4554W
α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease.
α-synuclein  
Parkinson's Disease  
/
HY-W654000 Cyclic GMP-13C,15N2
Cyclic GMP-13C,15N2 is 13C and 15N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses.
Isotope-Labeled Compounds   Endogenous Metabolite  
Infection   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-122958 Peucedanocoumarin III
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.
α-synuclein  
Parkinson's Disease  
/
HY-P991342 CQY684
CQY684 (PCA062 antibody) is a monoclonal antibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer.

Species: Human

Cadherin  
Breast Cancer   Esophageal Cancer  
/
HY-B1039AS Ambroxol-d5 hydrochloride
Ambroxol-d5 (hydrochloride) is the deuterium labeled Ambroxol hydrochloride. Ambroxol hydrochloride (NA-872 hydrochloride), an active metabolite of the proagent Bromhexine, has potent expectorant effects. Ambroxol hydrochloride is a glucocerebrosidase (GCase) chaperone and increases glucocerebrosidase activity. Ambroxol hydrochloride induces lung autophagy and has the potential for Parkinson disease and neuronopathic Gaucher disease research.
Isotope-Labeled Compounds   Glycosidase   Autophagy  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-125515 Tetrahydroharmine
Tetrahydroharmine (Leptaflorine) is a selective reversible monoamine oxidase A (MAO-A) inhibitor with an IC50 of 74 nM. Tetrahydroharmine can be used for the research of parkinson’s disease.
Monoamine Oxidase  
Depression   Parkinson's Disease  
/
HY-D0193A Ponceau 4R (85%)
Ponceau 4R (85%) (Acid Red 18 (85%); New Coccine (85%)) is an orally active synthetic food colorant and a HSA-binding aggregator. Ponceau 4R (85%) binds to HSA, inducing its partial unfolding, conformational changes and aggregation. Ponceau 4R (85%) serves as a food colorant and can be used in research on diseases including type Ⅱ diabetes, Parkinson's disease, Huntington's disease and spongiform encephalopathy.
Environmental Pollutants   Drug Derivative  
Autoimmune Disease   Parkinson's Disease   Huntington's Disease  
/
HY-P99562 Tidutamab
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).

Species: Human

CD3  
Cancer  
/
HY-D2871 DAyne
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-G0017S N-Desmethyl imatinib-d8
N-Desmethyl imatinib-d8 is a deuterium labeled Imatinib metabolite N-Desmethyl Imatinib (HY-G0017). N‑Desmethyl imatinib (Norimatinib) is an active metabolite of Imatinib (HY-15463), a selective c‑Abl inhibitor, and a substrate of P‑glycoprotein. N-Desmethyl imatinib binds to the c-Abl catalytic domain to prevent substrate phosphorylation, inhibits c-Abl-mediated α-synuclein activation and downstream inflammatory signaling pathways. N-Desmethyl imatinib induces apoptosis in K562 human leukemia cells. N-Desmethyl imatinib exhibits significantly elevated plasma levels in gastrointestinal stromal tumor (GIST) settings following mild SARS CoV 2 infection. N-Desmethyl imatinib can be used for the research of Parkinson’s disease, gastrointestinal stromal tumor, and chronic myeloid leukemia.
Isotope-Labeled Compounds   Drug Metabolite   P-glycoprotein   Apoptosis  
Cancer   Parkinson's Disease  
/
HY-D1504 IR-797 chloride
IR-797 chloride is a near-infrared (NIR) dye. IR 797 has absorption maxima near 700 nm. IR-797 shows some aggregation-induced-emission (AIE) properties. IR-797 shows shows cytotoxic.
Fluorescent Dye  
Cancer  
/
HY-114118S1 Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
Isotope-Labeled Compounds   GLP Receptor   Insulin Receptor   α-synuclein   Apoptosis   p38 MAPK   Autophagy   Bcl-2 Family  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N2163 Mudanpioside C
Mudanpioside C is a protein disulfide isomerase (PDI) inhibitor with a human IC50 of 3.31 μM and human Kd of 3.9 μM. Mudanpioside C suppresses collagen-induced platelet aggregation, interferes with platelet activation, adhesion, and spreading. Mudanpioside C can be used for the research of cardiovascular diseases.
PDI  
Cardiovascular Disease  
/
HY-W002458 4-Nitropyrazole
4-Nitropyrazole is a five-membered nitrogen-containing heterocyclic compound that can be used as a drug intermediate. 4-Nitropyrazole can be synthesized into antibiotics/antifungal/antiviral agents containing pyrazole rings. 4-Nitropyrazole is synthesized through C-H activation reactions to produce LRRK2 inhibitors, which are used in the research of Parkinson's disease.
Drug Intermediate  
/
HY-N10568 Gibberellin A9
Gibberellin A9 is a plant hormone that targets gibberellin receptor GID1. Gibberellin A9 binds to GID1 to form a GA-GID1-DELLA protein complex, which promotes the degradation of DELLA proteins. This relieves the inhibitory effect of DELLA proteins on plant growth, thereby promoting plant cell elongation and division, and increasing seed germination rate. Gibberellin A9 is promising for use in studies on plant growth and development, such as stem elongation and flowering induction.
Phytohormone  
/
HY-150058 Bocconoline
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD).
Others  
Neurological, Eye or Ear Disease  
/
HY-W856375A BSPOTPE
BSPOTPE is the mixture of (E)-BSPOTPE (HY-W856375) and (Z)-BSPOTPE. BSPOTPE binds Human serum albumin (HSA) (HY-P1956), exhibits aggregation-induced emission (AIE) phenomenon. BSPOTPE shows selectivity for albumin (such as HSA and BSA), but has no obvious fluorescence response to other proteins and DNA. BSPOTPE can be used as fluorescent probe for HSA.
Fluorescent Dye  
/
HY-P10019 Pegsebrenatide
Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension. Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis. Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis.
GCGR  
Parkinson's Disease   Experimental Autoimmune Encephalomyelitis   Glaucoma   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis  
/
HY-P4808 PHF6
PHF6 (VQIVYK) is a self-assembly sequence capable of initiating the full-length tau protein aggregation and is mapped to the third microtubule-binding repeat region of the tau protein.
Amyloid-β   Autophagy  
Neurological, Eye or Ear Disease  
/
HY-P11498 Cyclomarin monomer-2
Cyclomarin monomer-2 (Compound 10), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-2 binds to the Mtb ClpC1 protein with a KD of 4.0 nM. The MIC of Cyclomarin monomer-2 against the Mtb H37Rv standard strain is 3.1 μM. Cyclomarin monomer-2 can be used as a key intermediate in the development of Homo-BacPROTACs.
Drug Intermediate   Bacterial  
Mycobacterium Tuberculosis Infection  
/
HY-B2134 Casanthranol
Casanthranol is a naturally derived, orally active mixture of anthraquinone glycosides that exhibits inhibitory activity against α-synuclein and bioactivities related to laxation. Casanthranol inhibits seed-induced α-synuclein fibrillation in cell-free systems and rescues preformed fibril-induced cytotoxicity in differentiated N2a cells. Casanthranol promotes intestinal transit in both the small and large intestines of mice with experimental constipation. Casanthranol can be used in research related to constipation.
α-synuclein  
Digestive System Disease  
/
HY-N0293R Paeoniflorin (Standard)
Paeoniflorin (Standard) is the analytical standard of Paeoniflorin. This product is intended for research and analytical applications. Paeoniflorin is a heat shock protein-inducing compound and commonly exists in the plants of Paeoniaceae family, with various biological activities, including anticancer activity, anti-inflammatory activity, enhancing cognition and attenuating learning impairment, anti-oxidative stress, antiplatelet aggregation, expansion of blood vessels, and reducing blood viscosity.
Reference Standards   HSP  
Cancer   Infection   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-D1456 TEPC466
TEPC466 is a novel TEPP-46-based aggregation-induced emission (AIE) probe. TEPC466 shows a high degree of selectivity and sensitivity for the detection of PKM2 protein via the AIE effect. EPC466 can be used for the detection of PKM2. TEPC466 is successfully applied in imaging the PKM2 protein in colorectal cancer cells with low toxicity. TEPC466 is a useful tool for cancer diagnosis and research.
Pyruvate Kinase  
/
HY-N2991 Dehydropachymic acid
Dehydropachymic acid is one of the major triterpenes isolated from Poria cocos. Dehydropachymic acid is more effective in autophagy-lysosome pathway (ALP) impaired cells rather than normal cells.
Autophagy  
Neurological, Eye or Ear Disease  
/
HY-P11497 Cyclomarin monomer-1
Cyclomarin monomer-1 (Compound 5), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-1 binds to the Mtb ClpC1 protein with a KD of 3.5 nM. The MIC of Cyclomarin monomer-1 against the Mtb H37Rv standard strain is 1.6 μM. Cyclomarin monomer-1 can be used as a key intermediate in the development of Homo-BacPROTACs.
Drug Intermediate   Bacterial  
Mycobacterium Tuberculosis Infection  
/
HY-W042156 Aegeline
Aegeline, a main alkaloid, mimics the yeast SNARE protein Sec22p in suppressing α-synuclein and Bax toxicity in yeast. Aegeline restores growth of yeast cells suppressed by either αsyn or Bax. Antioxidant activity.
Fungal  
Fungal Infection   Parkinson's Disease  
/
HY-157036 INSA
INSA is a a pH-sensitive fluorescent probe. INSA can simultaneously light up mitochondria (red emission) and lysosomes (green emission) for their internal pH differences.
Fluorescent Dye  
/
HY-N1163 Tetrahydroalstonine
Tetrahydroalstonine ((-)-Tetrahydroalstonine) is an indole alkaloid and a selective α₂-adrenergic receptor antagonist. Tetrahydroalstonine exhibits certain neuroprotective effects. Tetrahydroalstonine can regulate autophagy-lysosomal function by activating the Akt/mTOR pathway, significantly reducing OGD/R-induced primary cortical neuronal injury.
Adrenergic Receptor   Atg8/LC3   Akt   mTOR  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N0698 Crocin II
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.
Endogenous Metabolite   α-synuclein  
Cancer   Parkinson's Disease  
/
HY-W100287 Murrayafoline A
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
NF-κB   p38 MAPK   Interleukin Related   IKK   JNK   β-catenin   Wnt  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Parkinson's Disease   Hypertension   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-W011831 NDSB-256
NDSB-256 is a non-stain remover sulfabetaine. NDSB-256 prevents protein aggregation and promotes denaturation of chemically and thermally denatured proteins.
Biochemical Assay Reagents  
/
HY-P5979 LRRKtide
LRRKtide is a polypeptide substrate. LRRKtide is a specific phosphorylation substrate of LRRK2, a kinase associated with Parkinson's disease, and its phosphorylation site is a threonine residue. LRRKtide can be used for characterization of the catalytic properties of LRRK2, as well as studies on kinase activity and inhibition. LRRKtide is applicable to research related to Parkinson's disease.
LRRK2  
Parkinson's Disease  
/
HY-W127502 1-Hexadecyl lysophosphatidic acid
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.
Biochemical Assay Reagents  
/
HY-W115752 Hydrazine sulfate (99%)
Hydrazine sulfate is an orally active PEPCK inhibitor. Hydrazine sulfate inhibits PEPCK and low-Km ALDH. Hydrazine sulfate impairs gluconeogenesis and enhances the protective effect of energy substrates against MPP+ toxicity. Hydrazine sulfate exacerbates liver damage in rats when combined with Ethanol. Hydrazine sulfate can be used in the research of shock, non-small cell lung cancer, colorectal cancer and Parkinson's disease.
PEPCK   Aldehyde Dehydrogenase (ALDH)  
Metabolic or Endocrine Disease   Lung Cancer   Colorectal Cancer   Salmonella Infection   Parkinson's Disease  
/
HY-B0228S Adenosine-d1
Adenosine-d is the deuterium labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Nucleoside Antimetabolite/Analog   Autophagy   Apoptosis   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-P99648 Gosuranemab
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.

Species: Human

Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-118159 Diphenyl-1-pyrenylphosphine
Diphenyl-1-pyrenylphosphine (DPPP) is a functional organic molecule with both fluorescent properties and metal coordination ability, which is commonly used in materials and coordination chemistry research. Upon exposure to ultraviolet light, Diphenyl-1-pyrenylphosphine undergoes photoinduced phosphorus atom oxidation to form O-DPPP, triggering a transition from aggregation-induced emission (AIE) to aggregation-caused quenching (ACQ). Diphenyl-1-pyrenylphosphine reacts stoichiometrically with lipid hydroperoxides to produce fluorescent diphenyl-1-pyrenylphosphine oxide. Diphenyl-1-pyrenylphosphine can insert into cell membranes to monitor lipid peroxidation processes in living cells.
Fluorescent Dye  
/
HY-110028 Leelamine hydrochloride
Leelamine hydrochloride is an orally active weakly basic amine that inhibits NPC1 and the androgen receptor AR-V7, and acts as a cannabinoid receptor agonist. Leelamine hydrochloride also functions as a lysosome affinity agent that blocks endocytosis, disrupts autophagic flux and cholesterol transport, thereby altering the RTK-AKT/STAT/MAPK signaling cascade. Leelamine hydrochloride induces cancer cell death and autophagosome accumulation, and can be used in research related to melanoma, castration-resistant prostate cancer and breast cancer.
Cannabinoid Receptor   Androgen Receptor  
Breast Cancer   Prostate Cancer   Melanoma   Obesity  
/
HY-NP009 α-Lactalbumin
α-Lactalbumin is a globular whey protein that exists in milk. α-Lactalbumin binds Ca2+, Mg2+, Mn2+, Na+, K+ and Zn2+ ions; among these, Ca2+ binding enhances protein stability, while Zn2+ binding reduces stability and induces aggregation. α-Lactalbumin forms amyloid fibrils, amorphous aggregates, nanoparticles and nanotubes depending on external conditions. α-Lactalbumin exhibits bactericidal and antiviral activities. α-Lactalbumin has anxiolytic and antidepressant activities, and its effects are enhanced under stress conditions.
Bacterial  
Infection   Depression   Anxiety or Fear-Related Disease  
/
HY-P4808A PHF6 TFA
PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein.
Amyloid-β   Autophagy  
Neurological, Eye or Ear Disease  
/
HY-117469 Triptohypol C
Triptohypol C, a Tripterin (HY-13067) derivative, is a potent Nur77-targeting anti-inflammatory agent with an Kd value of 0.87 μM. Triptohypol C inhibits inflammatory response by promoting the interactions of Nur77 with TRAF2 and p62/SQSTM1.
Nuclear Hormone Receptor 4A/NR4A   p62  
Inflammation or Immune System Disease  
/
HY-P4704A α-Synuclein (61-95) (human) TFA
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-B0228S11 Adenosine-15N5
Adenosine-15N5 (Adenine riboside-15N5; D-Adenosine-15N5) is the 15N labled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds  
Cancer  
/
HY-P10409 SHLP2
SHLP2 (Small humanin-like peptide 2) is a small molecule peptide encoded by mitochondrial DNA, belonging to mitochondria derived peptide. SHLP2 has the activity of regulating apoptosis and inhibits cell death. SHLP2 binds to mitochondrial complex 1. SHLP2 improves mitochondrial metabolism by increasing respiration and biogenesis, reducing ROS, and decreasing mtDNA oxidation. SHLP2 also regulated energy homeostasis through the activation of hypothalamic neurons. SHLP2 can be used in the study of diseases related to mitochondrial dysfunction and anti-aging diseases, such as age-related macular degeneration and Parkinson’s disease.
Apoptosis   Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P9995 Posdinemab
Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease.

Species: Human

Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-W010041 Scyllo-Inositol
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
α-synuclein   Amyloid-β  
Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
/
HY-W042557 Tetrabutylammonium trifluoromethanesulfonate
Tetrabutylammonium trifluoromethanesulfonate, commonly known as TBAOTf. TBAOTf is widely used as a strong acid catalyst and phase transfer agent in organic synthesis, especially for reactions involving nucleophilic substitution, elimination, and rearrangement, in addition, it is also used as an electrolyte additive for rechargeable batteries and a stabilizer of supercritical fluids Due to its high stability, solubility and selectivity, TBAOTf is considered to be a highly efficient and multifunctional reagent in various applications.
Biochemical Assay Reagents  
/
HY-P991728 Zarutatug
Zarutatug (TORL-3-600 antibody) is an IgG1κ humanized antibody targeting cadherin 17 (CDH17). It selectively binds to cell-surface CDH17, triggering endocytosis and trafficking to lysosomes. Zarutatug can be used to construct ADCs, such as TORL-3-600.

Species: Human

Cadherin   ADC Antibodies  
Cancer  
/
HY-B0228S13 Adenosine-13C10
Adenosine-13C10 (Adenine riboside-13C10; D-Adenosine-13C10) is 13C-labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Isotope-Labeled Compounds   Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Autophagy   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-P990762 Seniprutug
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis.

Species: Human

Others  
Inflammation or Immune System Disease   Arthritis  
/
HY-P99356 Cinpanemab
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.

Species: Human

α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-157839 PROTAC α-Synuclein/Tau degrader 1
PROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with KDs of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinson’s disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803)).
PROTACs   α-synuclein   Tau Protein  
Parkinson's Disease  
/
HY-P99405 Prasinezumab
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research.

Species: Human

α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P99471 Bepranemab
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease.

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-D1711 MHI-148
MHI-148 is a near-infrared heptamethine cyanine dye with tumor-targeting properties for cancer detection, diagnosis and research. MHI-148 is immediately taken up and accumulated by lysosomes and mitochondria of tumor cells, but not in lysosomes and mitochondria of normal cells.
Fluorescent Dye  
Cancer  
/
HY-P9969 Matuzumab
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab.

Species: Human

EGFR  
Lung Cancer  
/
HY-P99956 Zilovertamab vedotin
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Antibody-Drug Conjugates (ADCs)   Apoptosis  
/
HY-40294 Indazole
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
Monoamine Oxidase   GSK-3   LRRK2  
Pancreatic Cancer   Bacterial Infection   Depression   Cardiovascular Disease   Alzheimer's Disease   Parkinson's Disease   Obesity  
/
HY-B0228S1 Adenosine-13C5
Adenosine-13C5 is the 13C labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
Apoptosis   Nucleoside Antimetabolite/Analog   Autophagy   Endogenous Metabolite  
Cancer  
/
HY-DY1040 LysoTracker Red (solution)
LysoTracker Red (solution) is a Red fluorescently labeled lysosomal probe with a maximum excitation/emission wavelength of 577/590 nm. The structure is composed of a fluorescein group and linked weak bases, which can freely cross the cell membrane and gather on spherical organelles. It is suitable for observing the internal biosynthesis and related pathogenesis of lysosomes.
Solvent and concentration: DMSO: 1 mM
Fluorescent Dye   Biochemical Assay Reagents  
/
HY-W007465 4-Aminobenzyl alcohol
4-Aminobenzyl alcohol is a self-eliminating linker. 4-Aminobenzyl alcohol can be used to synthesize the fluorescent probe MB-Van1 targeting Vanin-1.
Drug Intermediate  
Inflammation or Immune System Disease  
/
HY-P70660 SNCA Protein, Mouse
SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA Protein, Mouse is the recombinant mouse-derived SNCA protein, expressed by E. coli , with tag free.

Species: Mouse; Source: E. coli

/
HY-P74781 LAMP2/CD107b Protein, Mouse (HEK293, His)
The LAMP2/CD107b protein is a lysosomal membrane glycoprotein critical for lysosomal biogenesis, pH regulation, and autophagy.As a direct inhibitor of TMEM175, LAMP2 promotes lysosomal acidification and optimizes hydrolase activity.LAMP2/CD107b Protein, Mouse (HEK293, His) is the recombinant mouse-derived LAMP2/CD107b protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens NK Cell CD Proteins Monocyte CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-2/CD107b

/
HY-P702806 PRKN Protein, Human (His, SUMO)
PRKN Protein, Human (His, SUMO) is the recombinant human-derived PRKN, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P72526 LAMP1/CD107a Protein, Mouse (HEK293, His)
LAMP1/CD107a is a key lysosomal glycoprotein that regulates lysosomal biogenesis, pH, autophagy, and cholesterol homeostasis.It directly inhibits the TMEM175 proton channel, optimizing lysosomal acidity for efficient hydrolase activity.LAMP1/CD107a Protein, Mouse (HEK293, His) is the recombinant mouse-derived LAMP1/CD107a protein, expressed by HEK293 , with C-6*His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens NK Cell CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-1/CD107a

/
HY-P7779 LAMP1/CD107a Protein, Human (HEK293, Fc)
LAMP1/CD107a Protein, Human (HEK293, Fc) is a recombinant human CD107a expressed in HEK 293 cells with a C-Fc tag at the C-terminus. LAMP1/CD107a Protein can be used as a functional marker for the identification of natural killer cell activity.

Species: Human; Source: HEK293

CD Antigens NK Cell CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-1/CD107a

/
HY-P77435 LAMP3/CD208 Protein, Human (HEK293, His)
LAMP3/CD208 is a lysosomal glycoprotein that participates in the unfolded protein response (UPR) and contributes to protein degradation and cell survival, especially in the presence of proteasome dysfunction.It crucially promotes lysosome-autophagosome fusion and regulates autophagy.LAMP3/CD208 Protein, Human (HEK293, His) is the recombinant human-derived LAMP3/CD208 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens

/
HY-P7778 LAMP1/CD107a Protein, Human (HEK293, His)
LAMP1/CD107a Protein, Human (HEK293, His) is a recombinant human CD107a expressed in HEK 293 cells with a His tag at the N-terminus. LAMP1/CD107a Protein can be used as a functional marker for the identification of natural killer cell activity.

Species: Human; Source: HEK293

CD Antigens NK Cell CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-1/CD107a

/
HY-P76171 BLOC1S2 Protein, Human
BLOC1S2 is an essential component of the BLOC-1 complex and is critical for the biogenesis of lysosome-related organelles (LROs), including platelet dense granules and melanosomes. BLOC-1 cooperates with the AP-3 complex to direct membrane protein cargo into vesicles for delivery to neurites and nerve terminals, suggesting that it is involved in neurite extension. BLOC1S2 Protein, Human (GST) is the recombinant human-derived BLOC1S2 protein, expressed by E. coli , with no tagged.

Species: Human; Source: E. coli

/
HY-P76171A BLOC1S2 Protein, Human (N-GST)
BLOC1S2 is an essential component of the BLOC-1 complex and is critical for the biogenesis of lysosome-related organelles (LROs), including platelet dense granules and melanosomes. BLOC-1 cooperates with the AP-3 complex to direct membrane protein cargo into vesicles for delivery to neurites and nerve terminals, suggesting that it is involved in neurite extension. BLOC1S2 Protein, Human (N-GST) is the recombinant human-derived BLOC1S2 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

/
HY-P704891 SNCA Protein, Human (A53T)
Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA, Human (A53T) is the recombinant human-derived SNCA protein, expressed by E. coli, with C-His labeled tag.

Species: Human; Source: E. coli

/
HY-P74782 LAMP1/CD107a Protein, Rat (HEK293, Fc)
The LAMP1/CD107a protein is a lysosomal membrane glycoprotein that plays critical roles in lysosomal biogenesis, pH regulation, autophagy, and cholesterol homeostasis.It critically regulates lysosomal lumen pH by inhibiting the proton channel TMEM175, optimizing lysosomal acidification for efficient hydrolase activity.LAMP1/CD107a Protein, Rat (HEK293, Fc) is the recombinant rat-derived LAMP1/CD107a protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

CD Antigens NK Cell CD Proteins Stem Cell CD Proteins Platelet CD Proteins Erythrocyte CD Proteins Endothelial cell CD Proteins LAMP-1/CD107a

/
HY-P75969 PEAR1 Protein, Rat (sf9, His)
The PEAR1 protein is characterized by the absence of conserved residues critical for feature annotation propagation, prompting exploration of its structural and functional implications. This unique feature indicates potential changes in molecular interactions and biological activity. PEAR1 Protein, Rat (sf9, His) is the recombinant rat-derived PEAR1 protein, expressed by Sf9 insect cells , with C-His labeled tag.

Species: Rat; Source: Sf9 insect cells

Receptor Proteins

/
HY-P77436 LAMP3/CD208 Protein, Rhesus Macaque (HEK293, His)
The LAMP3/CD208 protein is a lysosomal membrane glycoprotein that actively participates in the unfolded protein response (UPR), aiding protein degradation and cell survival during proteasome dysfunction. It is essential for lysosome-autophagosome fusion, where it regulates the autophagy process. LAMP3/CD208 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived LAMP3/CD208 protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Source: HEK293

CD Antigens

/
HY-P702807 PRKN Protein, Human (sf9, His, Myc)
PRKN Protein, Human (sf9, His, Myc) is the recombinant human-derived PRKN, expressed by Sf9 insect cells , with C-Myc, N-10*His labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Transferases (EC 2)

/
HY-P702810 PRKN Protein, Mouse (GST)
PRKN Protein, Mouse (GST) is the recombinant mouse-derived PRKN, expressed by E. coli , with N-GST labeled tag. ,

Species: Mouse; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P704889 SNCA Protein, Human (HEK293, Fc)
Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA, Human (HEK293, Fc) is the recombinant human-derived SNCA protein, expressed by HEK293, with C-His labeled tag.

Species: Human; Source: HEK293

/
HY-P704892 SNCA Protein, Human (E46K)
Alpha-synuclein (SNCA) is a key neuronal protein that regulates synaptic activity, including vesicle transport and neurotransmitter release. As a monomer, it enhances vesicle exocytosis, promotes fusion and fusion pore expansion, and increases local Ca(2+) release. SNCA, Human (E46K) is the recombinant human-derived SNCA protein, expressed by E. coli, with C-His labeled tag.

Species: Human; Source: E. coli

/
HY-P704896 SNCA Protein, Mouse (His)
SNCA proteins are critical for synaptic activity and regulate vesicle trafficking and neurotransmitter release. As a monomer, it enhances the vesicle exocytosis process. SNCA, Mouse (His) is the recombinant mouse-derived SNCA protein, expressed by E. coli, with C-His labeled tag.

Species: Mouse; Source: E. coli

/
HY-P705391 SNCA Protein, Cynomolgus (His)

Species: Cynomolgus; Source: E. coli

/
HY-P706269 ¹⁵N-Labeled SNCA Protein, Human (His)

Species: Human; Source: E. coli

Isotope-Labeled Recombinant Proteins

/
HY-P706310 SNCA Pre-formed Fibrils Protein, Mouse (His)

Species: Mouse; Source: E. coli

/
HY-P80207 LAMP2 Antibody (YA713)
LAMP2 Antibody (YA713) is a non-conjugated and Mouse origined IgG1 monoclonal antibody, targeting to LAMP2. It can be used as a loading control antibody.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Loading Controls Antibodies Primary Antibodies

/
HY-P81739 Phospho-alpha Synuclein (Ser129) Antibody (YA1484)
Phospho-alpha Synuclein (Ser129) Antibody (YA1484) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-alpha Synuclein (Ser129).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P82054 PARK7/DJ1 Antibody (YA1799)
PARK7/DJ1 Antibody (YA1799) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PARK7/DJ1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86206 Parkin Antibody (YA5898)
Parkin Antibody (YA5898) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Parkin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84545 SQSTM1/p62 Antibody (YA4242)
SQSTM1/p62 Antibody (YA4242) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SQSTM1/p62.

Host: Mouse; Reactivity: Human, Mouse, Rat, Rabbit, Monkey

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86565 LAMP2 Antibody (YA6257)
LAMP2 Antibody (YA6257) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LAMP2.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87749 Phospho-Synuclein-α (Ser129) Antibody (YA7434)
Phospho-Synuclein-α (Ser129) Antibody (YA7434) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-Synuclein-α (Ser129).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80740 LAMP2 Antibody (YA310)
LAMP2 Antibody (YA310) is a non-conjugated and Rabbit origined IgG monoclonal antibody, targeting to LAMP2. It can be used as a loading control antibody.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Loading Controls Antibodies Primary Antibodies

/
HY-P811173 CD208 Antibody
CD208 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CD208.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811699 CD208 Antibody (YA10170)
CD208 Antibody (YA10170) is a Rabbit-derived and non-conjugated IgG recombinant monoclonal antibody, targeting to CD208.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80899A SQSTM1/p62 Antibody (YA062)(PBS only)
SQSTM1/p62 Antibody (YA062) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SQSTM1/p62.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82054A PARK7/DJ1 Antibody (YA1799)(PBS only)
PARK7/DJ1 Antibody (YA1799) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PARK7/DJ1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83254 alpha/beta Synuclein Antibody (YA2999)
alpha/beta Synuclein Antibody (YA2999) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha/beta Synuclein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84545A SQSTM1/p62 Antibody (YA4242)(PBS only)
SQSTM1/p62 Antibody (YA4242) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SQSTM1/p62.

Host: Mouse; Reactivity: Human, Mouse, Rat, Rabbit, Monkey

Monoclonal Antibodies Primary Antibodies

/
HY-P84954 LAMP1 Antibody (YA7077)
LAMP1 Antibody is a non-conjugated antibody, targeting to CD107a.

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P85380 alpha Synuclein Antibody (YA5072)
alpha Synuclein Antibody (YA5072) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to alpha Synuclein.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86127 alpha Synuclein Antibody (YA5819)
alpha Synuclein Antibody (YA5819) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86521 LAMP1 Antibody (YA6213)
LAMP1 Antibody (YA6213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LAMP1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86651 SQSTM1/p62 Antibody (YA6343)
SQSTM1/p62 Antibody (YA6343) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SQSTM1/p62.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86680 PGP9.5 Antibody (YA6372)
PGP9.5 Antibody (YA6372) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGP9.5.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86749 alpha Synuclein Antibody (YA6441)
alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86749A alpha Synuclein Antibody (YA6441)(PBS only)
alpha Synuclein Antibody (YA6441) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87714 Phospho-SQSTM1/p62 (Ser349) Antibody (YA7399)
Phospho-SQSTM1/p62 (Ser349) Antibody (YA7399) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-SQSTM1/p62 (Ser349).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80740A LAMP2 Antibody (YA310)(PBS only)
LAMP2 Antibody (YA310) is a non-conjugated and Rabbit origined IgG monoclonal antibody, targeting to LAMP2. It can be used as a loading control antibody.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Loading Controls Antibodies Primary Antibodies

/
HY-P811647 Parkin Antibody (YA10121)
Parkin Antibody (YA10121) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Parkin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811647A Parkin Antibody (YA10121) (PBS only)
Parkin Antibody (YA10121) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Parkin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82328A alpha Synuclein Antibody (YA2073)(PBS only)
alpha Synuclein Antibody (YA2073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86701 alpha Synuclein Antibody (YA6393)
alpha Synuclein Antibody (YA6393) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to alpha Synuclein.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-K0002 Bacterial Protein Extraction Reagent

MCE Bacterial Protein Extraction Reagent integrates both lysozyme and nuclease activities and is specifically formulated for E. coli lysis. It efficiently disrupts the peptidoglycan layer under mild conditions to rapidly release intracellular proteins. Simultaneously, the incorporated nucleases degrade genomic DNA/RNA, significantly reducing lysate viscosity and minimizing nucleic-acid interference, thereby preserving the native conformation and functional integrity of target proteins to the greatest extent.

Protein Biology Protein Sample Preparation Cell Lysis

/

Keywords

α-synuclein aggregation elimination | α-synuclein clearance | Parkinson disease | synucleinopathy | protein aggregation | proteostasis | autophagy-lysosomal pathway | chaperone-mediated autophagy | ubiquitin-proteasome system | targeted protein degradation | AUTOTAC | LAMP2A | p62/SQSTM1 | lysosome